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Overview
This dissertation includes five chapters. Chapter 1 is a review of literature
about the role of cytoskeletal intermediate filament proteins (IF) in cells, in
general, and in tumor cells, in particular. Special emphasis is laid on the IF
protein synemin, because it is the focus of the studies presented in this
dissertation. In Chapter 2 we present the results of investigations determining
how TGF-, all trans-retinoic acid, and inhibition of the Notch pathway regulate
synemin levels in U373-MG astrocytoma cells, HeLa cervical carcinoma cells,
and N2a neuroblastoma cells. In Chapter 3, we explore the utility of the proximity
ligation assay to study interactions between IF proteins and other cellular
proteins and detail how this assay should be optimized to yield conclusive
results. In Chapter 4 we have described experiments using PLA to gain
mechanistic insight into the synemin-PP2A interaction in astrocytoma and to
determine the domain on synemin responsible for binding to PP2A. In Chapter 5,
we have presented the overall conclusions we have drawn from the research
presented in Chapters 2, 3, and 4. All references cited in the dissertation are
presented in the bibliography after Chapter 5.
Note that Chapter 3 was published in Methods of Enzymology (568:537555, 2015) under the title “Synemin: Molecular Features and the Use of Proximity
Ligation Assay to Study its Interactions”. Therefore, Chapter 3 is presented in
agreement with the formatting guidelines provided by the professional journal in
which it was published. Chapters 1, 2, 4, and 5 have been presented according
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to the formatting guidelines stated in the dissertation preparation guide of the
Graduate School at the University of Memphis.
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ABSTRACT
Paul, Madhumita. PhD. The University of Memphis. December, 2016.
Intermediate Filament Protein Synemin: Regulation by Exogenous Factors and
Role in Astrocytoma Cell Proliferation through Interaction with Protein
Phosphatase 2A. Major Professor: Omar Skalli, PhD.
Intermediate filament proteins (IF) are cytoskeletal proteins that are
primary determinants of the mechanical strength of tissues. IF proteins also
modulate signaling pathways involved in cell death, survival, and growth. These
proteins are expressed in a tissue specific manner and their regulation is strictly
controlled in embryonic development and pathological conditions. Synemin is an
IF protein that, unlike other IF proteins, is expressed in a broad range of tissues
rather than in specific cell types. Synemin is expressed in all muscle types, glial
cells of the retina and optic nerve, hepatic stellate cells, some mature neurons of
the peripheral nervous system, and in astrocyte progenitors. The expression of
synemin in astrocyte precursor cells is developmentally regulated as these cells
stop expressing synemin after they mature into astrocytes. However, synemin is
re-expressed in mature astrocytes during brain injury and when astrocytes
become malignant (astrocytomas). Surprisingly, information about the factors
and/or signaling pathways regulating synemin expression in development and
disease is lacking.
Therefore, one of our goals was to determine which factors regulate
synemin protein levels in different tumor cells. To this end, we treated U373-MG
astrocytoma, HeLa cervical carcinoma, and N2a neuroblastoma cells with factors
that regulate expression of IF proteins other than synemin in tumor cells, such as
transforming growth factor- (TGF-), all-trans retinoic acid (ATRA), and v

secretase inhibitor-1 (GSI-1). Following each treatment, the protein levels of the
two major synemin isoforms ( and ) were compared between control and
treated cells by densitometry of Western blots. Our results demonstrated that the
levels of synemin are regulated by these agents in a cell-type dependent
manner. TGF- upregulated synemin in astrocytoma cells, but not in carcinoma
or neuroblastoma cells. This suggests that synemin is expressed during the
malignant transformation of astrocytoma due to regulation by factors such as
TGF-. On the other hand, ATRA and GSI-1, decrease synemin levels in
carcinoma and neuroblastoma cells, but not in astrocytoma cells. Since mature,
normal epithelial cells and peripheral neurons express little synemin, these
results suggest that synemin is expressed in carcinoma and neuroblastoma due
to the absence of differentiation factors in the tumor environment.
With regards to the role of synemin in tumors, our laboratory had shown
that synemin positively regulates the proliferation of astrocytoma cells by
antagonizing protein phosphatase 2A (PP2A). This prevents PP2A from
inactivating Akt, a kinase that promotes astrocytoma proliferation. These
previous studies also showed that synemin and PP2A co-immunoprecipitate.
However, these experiments did not reveal in which cellular compartments these
interactions took place. To answer that question and to examine in-situ the
interaction between synemin and PP2A, we used the newly developed proximity
ligation assay (PLA). Initial experiments showed that PLA is a very sensitive
technique. Therefore, we initiated experiments to optimize the conditions of the
assay, and in particular, titrating the dilutions of the different antibodies, as well
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as developed guidelines for the use of proper controls. Using these optimized
PLA conditions, we determined that synemin and PP2A interaction was localized
mainly in the nuclear region in astrocytoma cells. PLA also revealed that when
synemin is expressed, there is very little interaction between PP2A and Akt in
astrocytoma cells. However, when synemin is downregulated by shRNA, PP2A is
distributed in the cytoplasm of these cells. Also, there is increased interaction
between PP2A and Akt in synemin silenced astrocytoma cells. Therefore, these
results suggest that synemin binding to PP2A plays a role in determining the
cellular distribution of PP2A and in sequestering PP2A from Akt. This explains
that in synemin silenced astrocytoma cells, Akt remains phosphorylated and
active, enabling the astrocytoma cells to enter the cell cycle and proliferate. We
also used PLA to demonstrate that PP2A interaction with synemin involves
amino acids 700-1028 in the C-terminus of synemin, a region that has not
previously been found to bind with synemin interacting partners. These PLA data
were validated by proliferation rescue experiments.
Therefore, based on our results we conclude that synemin functions as a
scaffolding protein in astrocytoma cells. By binding to PP2A, synemin spatially
regulates its activity to control astrocytoma proliferation by regulating Akt
phosphorylation and activity. Our work also demonstrates the utility of the PLA
technique to study interactions between synemin and its binding partners in-situ.
These studies establish PLA as a valuable tool in studying interactions between
IF proteins other cellular proteins.
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Chapter 1: Introduction
1.1 Intermediate Filament Proteins: Structure and Assembly into Filaments
Observation of skeletal muscle cells by transmission electron microscopy
revealed the presence of cytoplasmic filaments with a diameter (10 nm)
intermediate between that of actin microfilaments (~6nm) and myosin filaments
(~15 nm) (Ishikawa, Bischoff, and Holtzer. 1968). Subsequent studies showed
that these intermediate sized filaments (IFs) are found in all vertebrate cells,
thereby establishing IFs as the third component of the cytoskeleton together with
microfilaments and microtubules. The three polymeric cytoskeletal components
are interconnected by linker proteins and together form an intricate network that
determines the mechanical properties, shape, and motility of cells and is
instrumental for chromosome segregation, cytokinesis, and organelle movement
(Kim and Coulombe. 2007). While the structure and biological functions of
microfilaments and microtubules have been studied extensively, many questions
remain about how IFs and their constitutive proteins contribute to cellular
processes and participate in signaling pathways.
IF proteins are encoded by over 70 different genes in the vertebrate
genome, which represents a fairly large gene family (Godsel, Hobbs, and Green.
2008). In addition, the mRNA product of some of these genes undergoes
alternate splicing, giving rise to an even larger number of IF proteins (Godsel,
Hobbs, and Green. 2008). IF proteins are grouped into six types based on
similarities in their gene structure, homology in the protein sequence of
conserved structural domains, and assembly properties (Godsel, Hobbs, and
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Green. 2008) (Table 1.1). Types I and II IF proteins comprise the acidic and
basic keratins, respectively. They are expressed primarily in epithelial cells and
form obligate heteropolymers containing a 1:1 molar ratio of acidic and basic
keratins. Type III IF proteins include: (1) desmin, present in all muscle types, (2)
vimentin, present in cells of mesenchymal origin and in cells that have undergone
epithelial to mesenchymal transition (EMT), (3) glial fibrillary acidic protein
(GFAP), expressed in mature astrocytes, and (4) peripherin, present in peripheral
neurons. Any type III IF protein can homopolymerize or form heteropolymers with
any other type III protein. Type IV IF proteins include neuron specific
neurofilament (NF) proteins, NF-H (heavy), NF- M (medium), and NF- L (light),
and α-internexin, present only in neurons of the central nervous system (CNS),
as well as synemin and nestin, which have a complex pattern of expression.
Nestin, synemin, and NF-H are unable to self-assemble into filaments, but can
incorporate into the network formed by type III IF proteins or NF-L in the case of
NF-H. While type I-IV IF proteins are present in the cytoplasm, type V IF includes
proteins present exclusively in the nucleus: the lamins A, B, and C. The different
lamin proteins cannot co-polymerize with cytoplasmic IF proteins but coassemble with each other to form the nuclear lamina, a complex structure lining
the inner aspect of the nuclear envelope (Zuela, Bar, and Gruenbaum. 2012).
Finally, the beaded filament proteins filensin and CP46 are present only in the
eye lens and are categorized by some authors as type VI IF proteins although
they lack some of the structural features that define true IF proteins (Omary.
2009).
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Table 1.1: Different groups of IF proteins, their tissue distribution, subcellular locations
and disease phenotypes associated with mutation in genes encoding IF proteins. Adapted
from (Godsel, Hobbs, and Green. 2008; Szeverenyi et al. 2008; Omary. 2009).
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All IF proteins share a distinct tripartite structure comprising a central helical rod domain flanked by non-helical and largely disordered amino (N) and
carboxyl (C) terminal domains, with the exception of lamins, in which the Cterminus tail comprises a small region with an immunoglobulin-like fold
(Chernyatina, Guzenko, and Strelkov. 2015). The rod domain of IF proteins
comprises four -helical subdomains (coil 1A, coil 1B, coil 2A, and coil 2B)
connected by non-helical linkers L1, L12, and L2 (Chernyatina, Guzenko, and
Strelkov. 2015; Herrmann et al. 2007). Coils 1A and 1B of the rod domain contain
seven-residue (heptad) HxxHxxx pattern where H represents a hydrophobic
amino acid such as isoleucine, leucine, valine or methionine, and x any amino
acid. The repetition of this pattern is largely responsible for the formation of a lefthanded, -helical, coiled-coil structure. The sub-helix, coil 2, has an elevenresidue (hendecad) periodicity in the N-terminus region of the segment that forms
parallel -helical bundles. The length of the helices, and their heptad and
hendecad periodicity, are conserved among members of the IF protein family. In
the middle of coil 1A and terminal part of coil 2B, there are two short sequences
that are also conserved across the IF family (Herrmann et al. 2009).
The structural features of the rod domain are important in the first step of
IF assembly, during which the rod domains of two IF polypeptides align in parallel
to form coiled-coil dimers. The next step is the lateral association of two dimers in
an anti-parallel, half-staggered manner to form tetramers or protofilaments that
assemble into unit length filaments (ULFs). Longitudinal annealing of ULFs forms
long apolar filaments (Figure 1.1) that undergo radial compaction to form mature
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IFs with 10 nm cross-sectional diameter (Herrmann et al. 2009; Godsel, Hobbs,
and Green. 2008). The coiled-coil structure and the higher order organization of
IFs endow these filaments with unique biomechanical characteristics. Atomic
force microscopy on single IFs has revealed that they are highly flexible and
extensible (Qin, Buehler, and Kreplak. 2010). IFs have a persistence length that
is much shorter than microtubules and microfilaments which shows that IF are
more flexible and capable of withstanding larger mechanical strain than these
two other cytoskeletal components (Block et al. 2015). IFs also exhibit a strain
hardening process upon stretching wherein the filament diameter reduces by a
factor of 4 while resisting tensile forces of several nano-Newtons (nN) (Qin,
Buehler, and Kreplak. 2010). These biomechanical properties have proven
important in determining the resilience of tissues, especially the skin, in response
to mechanical stress (Lowery et al. 2015).
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Figure 1.1: Schematic representation of the main steps by which IF monomers assemble
into filaments. (a) IF monomers have a conserved tripartite structure consisting of a central helical rod domain flanked by carboxyl and amino terminals that are variable in length and amino
acid sequence. (b) The IF monomers first dimerize by the parallel alignment of the rod domains of
two IF monomers. (c) Next, two dimers associate laterally in an antiparallel manner to form apolar
tetramers, which are the smallest IF subunits observed in cells. (d) Eight tetramers assemble
laterally to form unit length filaments (ULFs). (e) The ULFs join end to end to form filaments of 16
nm diameter. (f) Finally, the filaments undergo lateral compaction to form mature IF that have a
diameter of ~10nm. Adapted from (Godsel, Hobbs, and Green. 2008; Robert, Hookway, and
Gelfand. 2016).

6

1.2 Roles of IF Proteins: Insights from Animal Studies and Human Diseases
Insights into the biological functions of IF proteins have been provided by
studies of dominant negative or knock out (KO) mutants of IF genes in tissue
culture and transgenic animal models as well as by mechanistic studies of the 72
or so human genetic diseases caused by mutations in IF coding genes
(Szeverenyi et al. 2008). Collectively, these studies have revealed that IF
proteins fulfill diverse roles both at the cell and tissue level.
1.2.1 Role of IF in Maintaining Cell Shape and Tissue Structure
A major role of IFs is in maintaining shape and mechanical integrity of
cells. This is very well established for epithelial cells where keratin IFs form a
network associated with cell-cell and cell-substratum adhesion junctional
complexes connecting cells with each other and with the basement membrane.
Therefore, it is not surprising that loss of function mutations in genes encoding
keratins are associated with cell fragility. For instance, mutations affecting keratin
14 and keratin 5 (the keratins expressed in basal epidermal keratinocytes) are
associated with a group of rare human diseases called epidermolysis bullosa
(EB) (Peters et al. 2001; Coulombe, Kerns, and Fuchs. 2009). In EB patients,
exposure to mechanical trauma causes loss of tissue integrity within the basal
layer of epidermal keratinocytes resulting in extensive skin blistering. The keratin
mutations involved prevent IF assembly and in some cases result in the
formation of keratin protein aggregates that are diagnostic of the most severe
forms of EB (Coulombe, Kerns, and Fuchs. 2009).
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Similarly, the absence of desmin in muscle cells of knock-out transgenic
mice causes cellular fragility that result in the degeneration of cardiac, skeletal
and smooth muscle in mice after birth (Milner et al. 1996; Li et al. 1997). This
effect is pronounced in more active muscles such as the cardiac and skeletal
muscles (Milner et al., 1996). Studies of these mice also showed that although
desmin is not required during muscle development, it is needed during muscle
regeneration to obtain proper myofibrillar assembly (Li et al. 1997). Desmin-null
mice also fatigued easily when subjected to intensive exercise (Li et al. 1997).
This is because of altered mitochondrial positioning in cardiac muscles in the
absence of desmin (Lindén et al. 2001). In desmin-deficient mice, the
mitochondria are no longer associated with the Z-lines and myofibrils, resulting in
insufficient supply of adenosine triphosphates (ATP) to cardiac muscles during
contraction. Repositioning of mitochondria away from sites where ATP is
required also increases pro-apoptotic signals that cause the cardiomyocyte
degeneration and calcinosis seen in heart of desmin-null mice (Lindén et al.
2001). In humans, mutations in the desmin gene cause a group of myofibrillar
myopathies characterized by disorganized desmin filament network and
accumulation of insoluble desmin aggregates (Bar et al. 2006).
Lamins, present in the nucleus of all metazoans, play an important role in
the maintenance of the architecture of the nuclear membrane and possibly in the
organization of the chromatin. Most vertebrate cells express lamin A/C, that are
alternate splice products of the same gene, and two types of lamin B (Dechat et
al. 2010). Lamin A has been primarily implicated in maintaining the structural
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integrity of the inner nuclear membrane. Investigation of different cell types in
lamin A KO mice show that absence of lamin A makes the nuclear envelope very
fragile (Sullivan et al. 1999; Nikolova et al. 2004). Lamin A/C deficient mouse
fibroblasts have increased nuclear deformation and severely attenuated
transcriptional activation that impairs viability of mechanically strained cells
(Lammerding et al. 2004).
In neurons, NF triplet proteins have been demonstrated to determine the
radial diameter of axons. The NF triplet is composed of three distinct proteins:
NF-H (200 kDa), NF-M (160 kDa), and NF-L (68 kDa) which together polymerize
into the so-called neurofilaments, which are the names given to the IFs of
neurons. Homozygous mutation of NF-L gene in Japanese quail resulted in the
production of a truncated form of the protein that caused a reduction in the radial
growth of myelinated axons and a concomitant decrease in the speed of the
action potential resulting in a quivering behavior (Yamasaki et al. 1992).
Similarly, in NF-L and NF-M KO mice there was dramatic reduction in axonal
radial growth and delays in nerve regeneration after injury (Xu et al. 1996). In
contrast, NF-H KO mice did not consistently affect the radial growth of axons,
and the functional role of that protein remains unclear. The C-terminal
phosphorylation of NF proteins was also shown to be instrumental in determining
the axonal caliber by increasing the overall negative charge, thereby causing the
repulsion of the carboxyl terminal side arms of these proteins (Yuan et al. 2012).
This caused the carboxyl terminals to “stick out” radially from the neurofilaments,
thereby increasing the spacing between individual neurofilaments while also
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increasing crossbridges between neurofilaments and microtubules (Yuan et al.
2012).
1.2.2 Role of IF in Cell Migration
The first IF protein implicated in cell motility was vimentin because it was
noted in early studies that during embryonic development, cells migrating over
the neural crest and primitive streak contain an abundance of that protein
(Franke et al. 1982). This led to the assumption that vimentin may be important
for morphogenesis events during early development. However, the generation of
vimentin null mice who developed seemingly normally demonstrated that
vimentin is dispensable for cell migration during development (Colucci-Guyon et
al. 1994). A role for vimentin in migratory events taking place during wound
healing was suggested by the finding that lack of vimentin impaired the migratory
capacity of fibroblasts in adult vimentin KO mice and severely reduced the
capacity of these fibroblasts to invade 3-dimensional collagen lattice (Eckes et al.
2000).
Enhanced metastatic potential of several types of malignancies is strongly
correlated with overexpression of vimentin. A major event in determining the
metastatic properties of epithelial cells is the epithelial-mesenchymal transition
(EMT) where epithelial cells, mostly characterized by a cuboidal shape and
apical-basal polarity, from the primary tumor site assume a flattened and
elongated (mesenchymal) morphology and become more motile (Braga. 2000;
Mendez, Kojima, and Goldman. 2010). Vimentin has emerged as a key marker of
EMT and a clinical marker of metastatic potential and poor patient prognosis
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across a variety of carcinomas (Mendez, Kojima, and Goldman. 2010; Hu et al.
2004). Indeed, vimentin is upregulated in several epithelial cancers as they
increase their metastatic potential, such as in hepatocellular, prostate, and breast
carcinomas (Hu et al. 2004; Wei et al. 2008; Burch, Watson, and Nyalwidhe.
2013; Whipple et al. 2008). Expression of vimentin in carcinoma cells that do not
express vimentin revealed the importance of that protein in EMT-associated
change in cellular shape and migratory status (Mendez, Kojima, and Goldman.
2010).
Further supporting a role of vimentin in some migratory events, scrapewound healing experiments with MCF10A breast tumor cells showed that cells
increase vimentin expression as they migrate towards the lesion site (Gilles et al.
1999). On reaching the wound site and closing the lesion, the stationary cells
cease expressing vimentin (Gilles et al. 1999). In addition, skin wounds in
vimentin-null mice also took longer to close due to delayed appearance of
vimentin-rich myofibroblasts at the wound site and failure of these vimentin
negative myofibroblasts to contract adequately to pull together the wound edges
(Eckes et al. 2000).
Of note, the expression of keratin proteins is modified in epidermal cells
during wound healing, presumably to help in the repair process. In the intact skin,
terminally differentiated keratinocytes of the suprabasal layer express keratin 1
and keratin 10 (Magin, Hesse, and Schröder. 2000). However, after a wound, the
keratinocytes at the edge of the wound begin expressing keratin 6, keratin 16
and keratin 17. Upon wound closure, these activated keratinocytes downregulate
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keratin 6, keratin 16 and keratin 17 and up-regulate keratin 1 and keratin 10
(Magin, Hesse, and Schröder. 2000; Paladini et al. 1996).
In the CNS, GFAP and vimentin are both essential for the response of this
tissue to injury. Mechanical trauma to the CNS increases expression of GFAP
and vimentin in astrocytes which undergo hypertrophy and form a dense glial
scar at the injury site (Galou et al. 1996). Pekny et al. (Pekny et al. 1999) showed
that in GFAP and vimentin double KO mice, a less dense glial scar is formed at
the site of a brain or spinal cord lesion and is frequently accompanied by
bleeding. This shows that presence of GFAP and vimentin is essential in the
healing process after trauma in the CNS. Collectively, these studies show that
various IF proteins play an important role in cell migration both during tissue
repair and metastasis.
1.2.3 Protective Role of IF Proteins
Some keratins are important in helping cells resist metabolic challenges.
In hepatocytes, keratin 8 and keratin 18 contribute to drug and stress resistance
(Toivola et al. 1997). In humans, mutations in keratin 8, keratin 18, and keratin 19
have been shown to increase susceptibility to liver disease (DePianto and
Coulombe. 2004). A naturally occurring mutation in human keratin 8 (G61C)
predisposes transgenic mice bearing this mutation to liver injury when challenged
by oxidative stress, because this mutation prevents phosphorylation of keratin 8
on Ser73 by stress activated protein kinase (SAPK) (Ku and Omary. 2006).
Keratins also protect hepatocytes from cytotoxic effects of drugs. For instance,
hyperphosphorylation of keratin 18 at Ser52 has been shown to protect
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hepatocytes from metabolic stress induced by the hepatotoxins griseofulvin and
microcystin (Ku et al. 1998).
1.2.4 Role of IF Proteins in Inflammation
Inflammation is a biological response to restore homeostasis and protect
tissues following mechanical, chemical and microbial insult. The role of IF
proteins in regulating the inflammatory process in tissues has been of interest
recently. In the epidermis, the crucial role of keratins in regulating and
maintaining epidermal barrier functions has been demonstrated in mice deficient
in keratin 1 (Roth et al. 2012). These keratin 1 null mice have grossly reduced
cornified envelopes that are indicative of defective terminal differentiation of
keratinocytes. Also, there is an increased expression of proinflammatory
cytokines in the skin and serum of keratin 1 KO mice suggesting a role of keratin
1 in local and systemic inflammatory processes (Roth et al. 2012). Keratin 5 and
keratin 14 null mice develop acute epidermal fragility that is reminiscent of EBS
(Coulombe, Kerns, and Fuchs. 2009). Incidentally, the embryos of keratin 5 KO
mice also show very high expression of proinflammatory cytokines which
correlates to high levels of antigen-presenting dendritic cells in the epidermis,
changes which are similar to what is observed in EBS patients (Roth et al. 2012).
Further, investigations on the role of IF proteins in the inflammatory
process Mor-Vakin et al (2002) showed that macrophages secrete vimentin in
response to proinflammatory cytokines. The secreted vimentin increases the
capacity of macrophages to kill bacteria by enhancing bacterial phagocytosis
(Mor-Vaknin et al. 2003). Studies have also shown that intradermal injection of
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agents that disrupt the NF proteins, along with microfilaments and microtubules,
in the hind paws of rats cause chronic hyperalgesia after exposure to
epinephrine, suggesting a role of NF in development of chronic pain following
inflammation (Dina et al. 2003). Thus, these studies add to the growing repertoire
of biological functions of IF proteins by revealing that they can be key players in
the inflammatory process of different tissues.
1.2.5 Role of IF Proteins in Glial Cells
Vimentin-null mice have reduced number of Purkinje and Bergman glia
cells in the cerebellum and have impaired motor functions that imply this protein
plays a role in neural development and motor function as these mice (ColucciGuyon et al. 1994). Studies have further shown that ablation of either vimentin or
GFAP changed the morphology of Bergman glial cells (Giménez y Ribotta et al.
2000). Interestingly, in vimentin-null and GFAP-vimentin double KO mice there
was a disorganization of myelin in the cerebellar white matter suggesting a role
of GFAP in maintaining myelin sheath of oligodendrocytes. Further, in a mouse
model of multiple sclerosis it was shown that GFAP-null mice developed
symptoms more severe than controls and that the astrocytes of these mice had
reduced structural stability with less adherence to the substratum and less
extended processes (Liedtke et al. 1998). Astrocytes from GFAP-null mice also
showed reduced capability to produce a fully functional blood-brain barrier in
endothelial cells, suggesting a role for GFAP in establishing this barrier (Pekny et
al. 1998). Taken together, these studies indicate that GFAP and vimentin are
important for proper glial functions.
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1.2.6 Importance of IF Proteins for Proper Cellular Functioning: Lessons
Gleaned from IF-pathies
Of the 73 different IF proteins encoded by the human genome, 34 are
associated with one or more human diseases (Szeverenyi et al. 2008).
Mutations in keratin 8, keratin 18, and keratin 19 predispose individuals to
liver disease (Guldiken et al. 2015; Ku et al. 1998). Some of these mutations
prevent the phosphorylation of these keratins, resulting in the formation of keratin
rich cytoplasmic inclusions called Mallory-Denk bodies, which are also found in
response to metabolic liver damage (Strnad et al. 2012; Omary et al. 2009).
Reduced phosphorylation of keratin 8 along with reduced levels of keratin 8,
keratin 18, and keratin 19 following acute inflammation in colonic mucosa of
patients of inflammatory bowel disease has been associated with impaired
colonic healing and increase predisposition of patients to colitis associated
cancer (Corfe et al. 2015).
Mutations in lamin B1 and lamin B2 genes have been shown to cause the
adult-onset autosomal dominant leukodystrophy (ADLD), a neurodegenerative
disorder characterized by a disorganized inner nuclear membrane and aberrant
accumulation of myelin (Butin-Israeli et al. 2012).
Improper formation of IF networks caused by mutant IF proteins is observed in
several human diseases. In the rare leukodystrophy called Alexander disease,
mutations in GFAP causes this protein to form aggregates (called Rosenthal
fibers) rather than filaments in the cytoplasm of astrocytes (Messing et al. 1998).
Altered phosphorylation dynamics disrupts transportation of NF and causes
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formation of NF aggregates in neurodegenerative diseases, such as amyotrophic
lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) (Shea et al. 2009),
and giant axonal neuropathy (GAN) (Mahammad et al. 2013). In conclusion,
studies of KO animal models and human diseases caused by mutant IF proteins
have revealed that these proteins, while contributing to the mechanical resilience
of cells, are also important regulators of different cellular processes.
1.3 Post Translational Modifications of IF Proteins: Impact on IF Structure
and Function
Post translational modifications (PTMs) of specific residues in the amino
and carboxyl domains of IF proteins, regulate the dynamics of IF organization
and the interactions between IF proteins and other cellular proteins (Leduc and
Etienne-Manneville. 2015) (Figure 1.2). PTMs of IF proteins have also been
implicated in the aberrant formation of IF aggregates that contribute to
pathogenesis of a host of diseases, including skin disorders, myopathies , liver
disorders and disease phenotypes reminiscent of premature ageing (Omary.
2009).
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Figure 1.2 Roles of phosphorylation of IF proteins. Several cellular properties are affected by
IF protein phosphorylation, which leads to IF reorganization, disassembly and aggregation
(shown in the central part of the figure). (a) Unlike most IF proteins, NF-M and NF-H are heavily
phosphorylated under basal conditions in the tail domain KSP motifs. This regulates axonal
calibre, stability and transport. In several disease conditions, IF hyperphosphorylation causes
deposition of cytoplasmic IF aggregates. (b) In neurodegenerative diseases,
hyperphosphorylated NF (pNF) aggregates accumulate in the neuron cell body, causing polarity
loss of pNFs. (c) Phosphorylation of K8 and K18 protects against hepatoxicity and apoptosis. (d)
Lamin A/C phosphorylation allows nuclear egress of herpesvirus. (e) Phosphorylation
disassembles nestin IFs in myoblasts to promote neuromuscular junction (NMJ) development by
facilitating acetylcholine receptor (AChR) dispersal. (f) Fasting-induced desmin phosphorylation
causes ubiquitination and proteasomal degradation of desmin causing muscle atrophy. (g) K5,
K17, K18 and vimentin phosphorylation facilitates their association with 14-3-3 protein to promote
cellular growth via several mechanisms. (h) K8 phosphorylation can either induce or inhibit cell
migration depending on the cell type and stimuli. However, vimentin phosphorylation is strongly
associated with promoting cell migration. Reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews. Molecular Cell Biology (Snider and Omary. 2014), copyright (2014).
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Phosphorylation is perhaps the most abundant and best-studied PTM in IF
proteins. It is facilitated by the presence of a large number of Serine/Threonine
phosphorylation sites in the proximity of Arginine or Lysine rich and Xaa-Ser-ProXaa motifs in the amino and carboxyl regions of most IF proteins (Omary et al.
2006). Phosphorylation of Serine/Threonine residues in the amino or carboxyl
domains of IF protein facilitates IF reorganization by allowing the dynamic
exchange of subunits between filaments and a small pool of unpolymerized IF
oligomers (Omary et al. 2006). The number of phosphorylated residues per IF
protein depends on the individual IF protein and tissue in which it is expressed
and is generally low under basal conditions (Omary et al. 2006). However, in
altered physiological and pathological settings the level of phosphorylation of IF
proteins increases several fold. In general, hyperphosphorylation of IF proteins
during early mitosis or in apoptosis-induced cellular stress, leads to disassembly
of IFs into tetramers (Eriksson et al. 2004; Homberg and Magin. 2014; Omary et
al. 2006). Return to phosphorylation baseline is effected by the rapid turnover of
phosphate on IF proteins which is mediated by protein phosphatases, including
protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) (Omary et al.
2006). In the case of vimentin IFs, these phosphatases are directly associated
with the filaments (Eriksson et al. 2004).
The role of cytoplasmic and nuclear IF protein phosphorylation has been
extensively studied during mitosis. In mitosis, cyclin-dependent kinase 1(Cdk1)
phosphorylate the amino and carboxyl terminals of the nuclear lamina IF proteins
lamins A and C (Torvaldson, Kochin, and Eriksson. 2015) while PKC
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phosphorylates lamin B1, also a nuclear lamina protein (Mall et al. 2012). As a
consequence of these phosphorylation events, the nuclear lamina disassembles,
thereby contributing to the breakdown of the nuclear envelope at the beginning of
mitosis. In the case of cytoplasmic IF proteins, hyperphosphorylation of vimentin
at Ser-55 by Cdk1/Cyclin B promotes vimentin filament disassembly during
mitosis (Chou et al. 1996). Interestingly, in cell types that coexpress vimentin with
nestin, phosphorylation of vimentin by Cdk1/Cyclin B alone is not sufficient to
drive vimentin IF disassembly. For this to occur, nestin also needs to be
phosphorylated by Cdk1/Cyclin B in order to enable vimentin IF mitotic
disassembly (Chou et al. 2003).
Phosphorylation of IF proteins also facilitates proper IF segregation
between daughter cells during cytokinesis. For instance, GFAP and vimentin are
phosphorylated by Rho-kinase and Aurora-B kinase at amino terminal
Serine/Threonine residues specifically at the cleavage furrow during cytokinesis
(Izawa and Inagaki. 2006). Mutation of the Aurora-B kinase and Rho-kinase
phosphorylation sites on GFAP and vimentin impair IF segregation in postmitotic
cells highlighting the importance of site specific phosphorylation in regulating IF
dynamics during and after mitosis (Izawa and Inagaki. 2006).
PTM of IF proteins is also critical in regulating the interaction of these
proteins with other cellular proteins during various cellular processes. For
instance, phosphorylated vimentin mediates association of the 14-3-3 adaptor
protein with beclin-1 to decrease cellular autophagy and increases Akt-mediated
tumorigenesis (Wang et al. 2012). Similarly, it has been speculated that
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phosphorylation of GFAP and vimentin allows dissociation of tumor suppressor
protein menin from GFAP/vimentin IFs and facilitates menin translocation to the
nucleus where it acts as a repressor of the transcription factor Jun D (LopezEgido et al. 2002).
In neurons, phosphorylation appears to regulate the association of
neurofilament proteins with motor proteins (Sihag et al. 2007). Phosphorylation of
the C-terminal head of NF-H restricts the association of neurofilament proteins
with the anterograde motor protein kinesin but not with dynein, which is a
retrograde motor protein. The phosphorylation-regulated differential association
of neurofilament proteins with motor proteins is instrumental in slowing axonal
transport and affecting axonal diameter (Yuan et al. 2012).
Phosphorylation of keratins and its impact on the interactions of keratins
with other cellular proteins has been extensively studied, particularly in response
to cellular stress. The activation of p38 mitogen activated protein kinase (p38MAPK) in keratinocytes plays a critical role in these cells during stress, after
wounding, and in migration (Woll, Windoffer, and Leube. 2007). In cultured
epithelial cells, orthovanadate-induced cellular stress was shown to promote
activation of p38-MAPK which then phosphorylates keratin 8 on Ser73 causing
keratin filaments to disassemble and form cytoplasmic aggregates (Woll,
Windoffer, and Leube. 2007). In oral squamous carcinoma cells, Sec8, a protein
involved in vesicle docking and exocytosis, regulates phosphorylation of keratin 8
on Ser73 by controlling extracellular signal-regulated kinase (Erk) or p38-MAPK
during cellular migration (Tanaka and Iino. 2015). In PANC-1 pancreatic
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carcinoma cells, cerulin, a toxin derived from skin of Australian green tree frog
(Litoria caerulea), induces keratin 8 phosphorylation by activating Erk and
downregulating PP2A to increase the migration and invasiveness of these cells
(Park and Lee. 2015). Collectively, these studies show that Erk and p38-MAPK
dependent keratin 8 phosphorylation are important in reorganizing keratin
cytoskeleton and providing the much needed flexibility in migrating keratinocytes.
1.4 Synemin and its Cellular Functions
Synemin was first described as an IF associated protein because it copurified with desmin and vimentin IF proteins from chicken smooth muscles but
was unable to polymerize into filaments on its own (Granger and Lazarides.
1980). However, later studies established synemin as an IF protein because the
cloned synemin cDNA was found to encode an amino acid sequence with
structural features and signature sequences typical of all IF proteins (see section
1.1 above) (Becker et al. 1995).
1.4.1 Structure and Assembly Properties of Synemin Isoforms
The gene encoding synemin is located in chromosome 15q26.3 in humans
(Mizuno et al. 2001) and chromosome 7 in mice (Xue et al. 2004). The synemin
gene is flanked by two microsatellite markers and is comprised of four introns,
five exons, and a 3’ untranslated region which is at least 3 kb long. The four
introns have the GT/AG splice site dinucleotide and their sizes are 6972, 13008,
2575, and 936 bp. The fourth intron of the synemin gene is at the end of the tail
domain and is used for alternative splicing and is not found in the other related IF
genes, such as NF H, M, and L, -internexin, and nestin. The synemin gene
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encodes three isoforms, ,  and L synemin, which are produced by alternative
splicing of the synemin pre-mRNA (Figure 1.3). All three synemin isoforms have
a short N-terminal containing approximately 10 amino acids and a rod domain of
~310 amino acids which ends with the IF protein signature sequence (Titeux et
al. 2001). However, the C-terminal domain of the three synemin isoforms is
variable in size. While synemin  and  have C-terminals of length 1246 and 934
amino acids respectively, the C-terminus of L-synemin is only 20 amino acids
long. Synemin has a larger C-terminal region than synemin due to the
retention of a 936 base-pair intronic sequence that is spliced out from the mRNA
of synemin. Thus, synemin is unique among IF proteins in that an intron is
used in the coding sequence of an alternately spliced isoform (Titeux et al. 2001;
Xue et al. 2004). In contrast to -synemin and -synemin, the C-terminal of Lsynemin has a unique amino acid sequence. This is due to the fact that the
mRNA of L-synemin is formed after splicing all four introns and skipping exon
4.The joining of exons 3 and 5 changes the translational reading frame and
produces a 20 aa (in human) and 36 aa (in mice) C-terminal peptide sequence
unique to L-synemin (Izmiryan et al. 2010; Xue et al. 2004).
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Figure 1.3 Schematic representation of the structure of synemin isoforms. The three
synemin isoforms have identical head and central rod domain, but differ in the tail domain. synemin contains the sequence of all the 5 exons of the synemin gene, whereas -synemin
contains in addition to the sequence encoded by intron IV. In L-synemin, exon 4 is spliced out
and intron IV sequence is absent. The number of amino acids (AA) and molecular weight (MW)
are those of human synemin isoforms. Molecular weight is indicated as calculated from the
protein sequence (actual) and as it appears after SDS-polyacrylamide gel electrophoresis (on
gels) (Paul and Skalli. 2016).

The three synemin isoforms are assembly-incompetent. Under normal
physiological conditions, purified synemin forms globular structures of ~11 nm
diameter (Bilak et al. 1998; Hirako et al. 2003). Similarly, in SW13.C2 cells, which
are devoid of cytosolic IF proteins, synemin forms non-filamentous aggregates
(Bellin et al. 1999; Titeux et al. 2001). Similar to synemin,  and L-synemin
cannot self-assemble into 10 nm filaments (Khanamiryan et al. 2008). Synemin
isoforms are incapable of forming filaments due to the small size of its Nterminus and that the rod domain is missing a TAAL sequence in helix 2A and
has the sequence TYRKLLEGEE in helix 2B mutated into TYRaLLEGEs. This
was shown by site-directed mutagenesis since mutated synemin containing the
100 amino-acids long N-terminal vimentin head domain, TAAL sequence in helix
2A and TYRKLLEGEE sequence in helix 2B of the rod domain was able to form
filaments (Khanamiryan et al. 2008). The TAAL and TYRKLLEGEE structural
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motifs are present in all type III IF proteins, such as vimentin, desmin, GFAP,
where they have been shown to be important for these proteins to polymerize
into IFs (Khanamiryan et al. 2008).
Although synemin by itself cannot form IFs in vitro and in vivo, it can
copolymerize in vitro with type III IF proteins, such as desmin, vimentin, GFAP
and peripherin (Bellin et al. 2001; Mizuno et al. 2001; Jing et al. 2007; Hirako et
al. 2003; Izmiryan et al. 2009). However, in the case of GFAP, synemin does not
get incorporated into GFAP IFs, but associates with the outer surface of these
filaments (Jing et al. 2007). Synemin can also form a cellular filamentous network
with type III IF proteins as shown by co-transfecting the cDNA for synemin and
that for a type III IF protein into cells lacking an endogenous IF network (Bellin et
al. 1999; Titeux et al. 2001; Jing et al. 2007).
1.4.2 Expression of Synemin is Developmentally Regulated and Varies
Under Normal and Pathological Conditions
Synemin is present in cell types belonging mostly to myogenic, neural and
mesenchymal lineages and its expression is regulated during development and
in disease processes. More specifically, in the adult, synemin is expressed in all
muscle cell types, in glial cells of the retina and optic nerve, in lens cells (Tawk et
al. 2003), in hepatic stellate cells (Schmitt-Graeff et al. 2006) and in some mature
neurons of the peripheral nervous system (Izmiryan et al. 2006). Synemin is also
present in the avian and amphibian erythrocytes (Granger and Lazarides. 1982;
Centonze, Ruben, and Sloboda. 1986).
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Expression of synemin varies among the three muscle groups. In smooth
muscles, and  synemin are present in equal amounts, while in striated
muscles synemin is the predominant isoform (Titeux et al. 2001; Hirako et al.
2003). In striated muscles, and  synemin are also present in different
subcellular locations. While -synemin is found associating predominantly with
cell-cell junction, synemin is associated with the Z disks (Lund et al. 2012).
Synemin is also present in myoepithelial cells, which are the only cell type
expressing keratin in which synemin is found. Blot overlay experiments suggest
that synemin may associate with keratin 5 and keratin 6 and incorporate into
keratin cytoskeleton in myoepithelial cells (Hirako et al. 2003).
During development, synemin isoforms have a very dynamic expression
pattern (Izmiryan et al. 2009). synemin is expressed in embryonic day 5 (E5)
before expression of synemin. By E7.5, synemin is expressed in the
embryonic mesoderm and neuroectoderm. By E10,  and  synemin are
coexpressed with vimentin in the limb and heart. In the nervous system,
expression of synemin isoforms is complex as the different isoforms are
coexpressed with different IF proteins during distinct developmental stages. Cells
of the neural crest that form the neurons of the dorsal root ganglia (DRG), start
expressing NF protein by E9 and E10 (Izmiryan et al. 2009). Once the peripheral
neuron precursors reach their destinations, the post mitotic neurons of the DRG
express  and  synemin in conjunction with peripherin, -internexin, nestin, and
the NF triplet protein. L-Synemin expression has been documented later in the
postmitotic neurons of the spinal ganglia at E13.
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In radial glial cells,  and  synemin expression coincides with that of
nestin and vimentin, prior to GFAP expression. As the radial glial cells undergo
morphological transformation into astrocytes, synemin expression increases in a
subset of GFAP+ astrocytes until post-natal day 2 (P2) (Sultana et al. 2000).
Thereafter, synemin levels decrease, and GFAP becomes the predominant IF
protein present in mature astrocytes (Sultana et al. 2000).
In addition to being developmentally regulated, synemin expression is also
influenced by pathological situations. Compared to normal astrocytes, synemin is
upregulated in astrocytes following traumatic brain injury, in Muller retinal glial
cells following retinal injury and in the highly malignant astrocytoma tumors (Jing
et al. 2007; Tawk et al. 2003; Jing et al. 2005). About one fourth of grade IV
astrocytoma tumors have high expression of synemin and it has been suggested
that the level of synemin expression in human astrocytomas could be of
prognostic value (Skalli et al. 2013). In addition, based on the expression of
synemin along with IF proteins nestin, GFAP and vimentin, grade IV astrocytoma
tumors can be divided into three categories: tumor subtype A consists of high
synemin, nestin and GFAP expression. Subtype B has low expression of all four
IF proteins, while subtype C has low expression of synemin, GFAP and vimentin
but high expression of nestin (Skalli et al. 2013). Considering that synemin
contributes to migratory and proliferative capacity of astrocytomas in vitro (Pan et
al. 2008) (see subsection 1.4.3), it may be speculated that astrocytoma subtypes
with different synemin expression levels also differ in their malignant properties.
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Synemin expression is also induced in specific cell types of the liver at
different stages of liver fibrosis and neoplasia. Synemin expression is
upregulated in hepatic stellate cells during inflammatory disease and in epithelial
cells of intrahepatic cholangiocarcinoma (Schmitt-Graeff et al. 2006; Liu et al.
2011). In breast tumor cells epigenetic silencing of synemin gene promoter in
myoepithelial cells has been shown to have a potential suppressive role in
human breast tumor cell lines (Noetzel et al. 2010). Synemin is also present in
HeLa cervical carcinoma cells, where it has been shown to interact with the LIM
domain phosphoprotein zyxin, which primarily localizes at focal adhesions and
along actin cytoskeleton (Sun et al. 2010). This interaction is important for
migration and adhesion of HeLa cells (Sun et al. 2010).
Taken together, these studies show that synemin is expressed in cells of
different lineages during development and pathological conditions. This suggests
a complex regulation of synemin gene expression in tissues and the possibility
that each isoform of synemin serves unique cellular functions.
1.4.3 Cellular Functions of Synemin
Synemin is important for muscle function as synemin null mice develop a
myopathic phenotype in which the mean diameter of skeletal muscle fibers is
decreased while susceptibility to injury following lengthening contractions is
increased. In addition, skeletal muscle sarcomeres in synemin null mice show
increased deformability in response to mechanical stress (Garcia-Pelagio et al.
2015).
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Synemin also maintains the structural integrity of muscle cells by
interacting with several structural and signaling proteins. In skeletal muscle cells,
synemin incorporates into the desmin filament network and interacts with nebulin
to anchor desmin IFs to the sarcolemma (Hirako et al. 2003). Additionally,
synemin interacts with vinculin, -actinin, talin, and plectin 1 to link desmin IFs to
the dystroglycan protein complex in the muscle costamere and to stabilize the
sarcolemma during muscular contraction (Bellin et al. 1999; Bellin et al. 2001;
Sun et al. 2008; Hijikata et al. 2008). It has also been reported that synemin
binds to zyxin, which is a LIM domain protein found at sites where actin interacts
with the cell membrane, via its C-terminal domain (Sun et al. 2010). Taken
together, these studies indicate that the interaction of synemin with integral
proteins in the myofibrillar Z-lines and costameres, and focal adhesions via its Cterminal region may be important in determining the role of synemin in
maintaining the structural integrity of muscle cells.
Furthermore, mice expressing the R349P mutant desmin, that is
associated with human desminopathies, showed disrupted binding of desmin
with synemin and the localization of synemin in cytoplasmic protein aggregates in
subsarcolemmal regions (Clemen et al. 2015). The implication of altered synemin
localization in myopathies involving desmin mutations is not clear. In smooth
muscles of peripheral vein, synemin has been shown to be downregulated during
primary vein incompetence which is a refractory disease of peripheral veins. The
authors of this study speculated that lower levels of synemin could affect the
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integrity of smooth muscle cells and the mechanical resilience of the vein wall
(Yin et al. 2006).
In addition to fulfilling a structural role in muscle by interacting with other
cytoskeletal protein, synemin may also influence muscle health by participating in
signaling pathways important for muscle function. This notion is supported by the
finding that in adult and neonatal cardiomyocytes synemin may function as an Akinase anchoring protein (AKAP) (Russell et al. 2006). Synemin localizes in the
M-band of the sarcomere in cardiomyocytes where it anchors the regulatory
subunit RII of protein kinase A (PKA RII) near myomesin and M-protein to
regulate their binding to titin and maintain sarcomere function (Prudner et al.
2014). Interestingly, synemin itself is a substrate for PKA-mediated
phosphorylation (Sandoval, Colaco, and Lazarides. 1983), but it is not known
how this phosphorylation affects synemin cellular functions. Studies in synemin
null mice have shown that expression of phosphorylated forms of signaling
proteins that control muscle mass, such as PKA-RIIa, CREB, Akt, is increased in
skeletal muscles following mechanical overload (Li et al. 2014). Thus, in skeletal
muscles, synemin may bind PKA and restrict its activity to prevent muscular
hypertrophy under normal physiological conditions (Li et al. 2014).
Synemin expression has also been documented in astrocytoma tumors
(Jing et al. 2005; Skalli et al. 2013) (see subsection 1.4.2), raising the question of
synemin’s role in astrocytoma cells. Studies of synemin in this context are
enabled by the fact that synemin is present in most established human
astrocytoma cell lines, including U373-MG, A172, U118-MG, Hs683, and SNB,
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but with the notable exception of U87 cells (Jing et al. 2005). In synemin-positive
astrocytoma cell lines, synemin distributes along the cytoplasmic vimentin and
GFAP network and is also present in cell membrane areas important for motility,
such as leading edges and ruffled membranes (Jing et al. 2005). In these
regions, synemin appears to interact with α-actinin rather than with vimentin and
GFAP. Altogether, these morphological investigations have suggested that
synemin plays a role in determining the motile properties of astrocytoma cells
(Jing et al. 2005; Pan et al. 2008). To explore this hypothesis, previous studies
from our laboratory showed that RNAi silencing of synemin in astrocytoma cells
decreased the amount of filamentous actin (F-actin) and the amount of -actinin
associated with F-actin (Pan et al. 2008). This suggested that, in these cells,
synemin influences the rate of association-dissociation of -actinin to F-actin in a
manner that favors the assembly and/or stabilization of F-actin. In addition, in
synemin-silenced cells, the reduced F-actin levels correlated with smaller cell
size, sharply decreased cell motility and delayed spreading on a substrate after
trypsinization (Pan et al. 2008).
Interestingly, these RNAi experiments also showed that in three different
types of astrocytoma cell lines (U373, U118 and Hs683), synemin
downregulation strongly reduced proliferation but that it did not cause apoptosis.
To further delineate the mechanism by which synemin contributed to proliferation
of astrocytoma cells, Pitre et al (2012) showed that synemin regulated activity of
protein phosphatase 2A (PP2A), which is a Serine/Threonine phosphatase, to
influence astrocytoma proliferation (details of this study are included in section
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4.1 of Chapter 4) (Pitre et al. 2012). As part of this dissertation, we have
continued to study the interaction between synemin and PP2A and its implication
in astrocytoma proliferation. We will discuss these studies in detail in Chapter 4
of this dissertation. The results obtained by Pitre et al (2012) indicated that the
mechanism by which synemin affects PP2A activity may involve the binding of
these two proteins since they were shown to co-immunoprecipitate. This study
was important because it identified a novel mechanism by which a cytoskeletal
protein, synemin, influences the proliferation of astrocytoma cells by altering
PP2A activity to increase levels of phosphorylated Akt in astrocytoma tumors
(Figure 1.4).

Figure 1.4: Hypothesized mechanism by which synemin regulates astrocytoma
proliferation. Synemin binds to PP2A in astrocytoma cells and prevents PP2A from
dephosphorylating Akt. This keeps Akt active by maintaining phosphorylation at sites that are
phosphorylated by mTORc2 and PDPK1. This allows astrocytoma cells to enter the cell cycle and
continue proliferation. Figure adapted from (Pitre et al. 2012).

31

1.4.4. Synemin: Questions Leading to the Research Undertaken in this
Dissertation
Synemin has several unique features when compared to the other IF
proteins known to us. First, unlike other IF proteins, synemin is not tissue-specific
in its distribution. Synemin is expressed in a variety of cells of different
embryological origin, including myogenic, neural, and mesenchymal lineages.
Second, the major synemin isoforms ( and ) have a C-terminus which is about
10 times larger than that of most other IF proteins. It is through the C-terminus
that  and  synemin engage in interactions with several cellular proteins. Finally,
synemin is one of the few IF proteins that are known to modulate signaling
pathways that regulate cell function, such as proliferation. Deleting or silencing
synemin expression has clear implications on the functional properties of cells.
Evidence of this has been provided by studies showing that synemin KO mice
develop a muscular dystrophy-like phenotype. Similarly, results of RNAi studies
from our laboratory have shown that synemin influences both the proliferation
and motility of astrocytoma cells. Information from these studies has prompted us
to learn more about the cellular functions of synemin in tumor cells.
There are several unknowns when it comes to defining the role(s) of
synemin in different cell types and the factors that regulate synemin expression
during development and in diseases. Also, considering that synemin interacts
with a large number of cellular proteins (refer to subsection 1.4.3), we know very
little about the functional consequences of these interactions. Thus, the first aim
of this dissertation is to identify factors that regulate the expression of synemin in
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different tumor cells (Chapter 2). Our second aim was to gain a better
understanding of the function of synemin in tumors by gaining mechanistic insight
into the association of synemin with its binding partners in these cells. For this
purpose we optimized the proximity ligation assay (PLA) which is a relatively new
technique of studying protein interactions in situ (Chapter 3). Finally, we have
used PLA to demonstrate that synemin physically interacts with PP2A in
astrocytoma cells. Furthermore, we have determined the PP2A binding domain
on synemin by using PLA and proliferation rescue assay (Chapter 4).
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Chapter 2: Regulation of Synemin Expression by TGF-, GSI-1 and ATRA in
Different Tumor Cell Lines
2.1 Introduction
During development and differentiation, the expression of IF proteins is
regulated in a cell and tissue specific manner. For instance, during myogenesis,
vimentin and nestin are replaced by desmin as myoblasts mature to form muscle
fibers (Lilienbaum et al. 1988). Similarly, vimentin and nestin are replaced by the
NF triplet proteins during neuronal differentiation (Cochard and Paulin. 1984),
while vimentin, nestin and synemin are replaced by GFAP during astrocyte
maturation (Sultana et al. 2000; Liu et al. 2002). Additionally, changes in the
composition and/or levels of IF proteins have been noted in cancer initiation and
progression (Satelli and Li. 2011) as well as in diseases that include skin
blistering disorders, myopathies, neuropathies, and premature ageing (LepinouxChambaud and Eyer. 2013; Banwell. 2001).
IF protein composition and/or expression levels in tumor cells may be
different from that of the non-malignant cell type from which they are derived. A
classic example of this principle is that of vimentin and keratin which, under
normal conditions, are present mostly in mesenchymal and epithelial cells,
respectively. However, some soft tissue sarcomas may express keratin in
addition to vimentin (Miettinen. 1991; Adegboyega and Qiu. 2008). Similarly,
melanomas, derived from vimentin-expressing melanocytes (Ramaekers et al.
1983) may express keratin 8/18 and/or nestin in addition to vimentin (Hendrix et
al. 1992; Florenes et al. 1994). Co-expression of vimentin with keratin 8/18 and
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nestin correlates with high metastatic and invasive properties of these tumors
(Hendrix et al. 1992; Florenes et al. 1994). Carcinomas are derived from keratinpositive and vimentin-negative cells. However, in some cases they express
vimentin in addition to keratin (Alkushi et al. 2003; Whipple et al. 2008). When
this occurs, vimentin expression is strongly associated with the EMT of
carcinoma cells progressing toward more malignant phenotypes (Iyer et al. 2013;
Mackinder et al. 2012).
Differences also exist between the IF protein composition of normal
astrocytes versus astrocytomas. In normal astrocytes, GFAP is expressed either
alone or along with vimentin (Ho and Liem. 1996; Lepinoux-Chambaud and Eyer.
2013). Astrocytoma tumors, on the other hand, express nestin and/or synemin in
addition to GFAP and vimentin (Jing et al. 2005; Skalli et al. 2013). Based on the
coexpression of GFAP, vimentin, synemin and nestin, grade IV astrocytomas are
grouped into three subclasses where one third of the tumors have high
expression of GFAP, nestin and synemin; one third have high vimentin and low
GFAP, nestin and synemin expression; and the remaining one third of the
astrocytoma tumors have low expression of all four IF proteins (Skalli et al.
2013).
Altogether, these findings demonstrate that IF proteins are regulated both
qualitatively and quantitatively during development and in carcinogenesis.
However, little is known about the factors and the underlying mechanisms that
bring about these changes. Most of the studies that have addressed these
questions have focused on epithelial cells. In mesothelial cells, retinoic acid
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increases cytokeratin expression but reduces vimentin levels and causes the
cells to assume a more differentiated epithelial morphology (Kim et al. 1987). In
contrast, epidermal growth factor (EGF) treatment of neonatal hepatocytes
(Pagan et al. 1997) and mesothelial cells (Connell and Rheinwald. 1983)
enhances vimentin expression and induces the proliferation of these cells. EGF,
however, does not affect vimentin protein levels in fibroblasts (Ferrari et al.,
1986). Sodium butyrate, an inhibitor of class I histone deacetylases (Vrba,
Trtkova, and Ulrichova. 2011; Davie. 2003), was shown to induce keratin 23
expression in pancreatic cancer cells and to arrest the proliferation and cause the
differentiation of these cells (Zhang et al. 2001). In metastatic basal cell-like
breast cancer cells vimentin gene expression is upregulated by
methyltetrahydrofolate dehydrogenase 2 (MTHFD 2) (Lehtinen et al. 2013).
Other studies have examined factors regulating GFAP expression in
astrocytes and astrocytoma tumors. Selmaj et al. (1991) showed that in primary
astrocytes tumor necrosis factor- (TNF- decreases GFAP protein levels but
does not affect vimentin protein levels (Selmaj et al. 1991). Fibroblast growth
factor (FGF), hydrocortisone, and prostaglandin F2a also upregulate GFAP
expression in astrocytes of the CNS and in Muller’s glial cells of the retina
(Morrison et al. 1985; Lewis et al. 1992). Retinoic acid has also been shown to
be an inducer of GFAP in normal astrocytes (Jang et al. 2004; Wohl and Weiss.
1998). Recently, Herrera et al (2010) showed that in astrocytes, retinoic acid
increased GFAP levels by linking the retinoic acid signaling pathway to the IL-6
cytokine stimulated JAK-STAT pathway (Herrera, Chen, and Schubert. 2010).
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Retinoic acid has a similar stimulatory effect on GFAP levels in malignant
astrocytoma cells that were overexpressing the cyclin dependent kinase inhibitor
(CDKI) p16ink4a, but whether this effect is also via the JAK-STAT cytokine
pathway is not known (Langlois et al. 2002).
Other studies have shown that the expression of nestin in astrocytoma
tumors is regulated by the notch pathway (Shih and Holland. 2006). Notch is a
family of transmembrane receptors that regulate cell-cell signaling (Zhou et al.
2010). Notch signaling is very active while determining cell fate during
development. Therefore, the control of nestin expression by notch has been
suggested to contribute to the development and maintenance of astrocytoma
cells in an undifferentiated and highly proliferative state (Shih and Holland. 2006).
Previous studies from our laboratory have suggested that the differences
in IF protein composition between different astrocytomas (Skalli et al. 2013)
could be due, at least in part, to growth factors binding to tyrosine kinase
receptors and extracellular matrix proteins (Sultana et al. 1998). (It should be
noted that Sultana et al. 1998 did not determine the effect of these growth factors
on synemin levels because at the time it was not known that astrocytoma cells
express synemin). These studies revealed that in U373-MG astrocytoma cells,
collagen IV decreased GFAP and nestin protein levels by 30% and 50%,
respectively (Sultana et al. 1998). These studies also showed that transforming
growth factor- (TGF- and EGF decrease GFAP protein levels by 50% in
U373-MG astrocytoma cells (Sultana et al. 1998) by downregulating the
transcriptional activity of the GFAP gene (Zhou and Skalli. 2000). Vimentin was
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modestly (20%) decreased in U373-MG astrocytoma after TGF- and EGF
treatment and this decrease was statistically significant. In contrast to GFAP and
vimentin, nestin protein levels were not affected by TGF- and EGF in U373-MG
astrocytoma cells (Sultana et al. 1998). This could be because the notch pathway
is responsible for regulating nestin expression in astrocytomas (Shih and
Holland. 2006). Considering that high grade astrocytomas are often
characterized by a decrease in GFAP and an increase in nestin protein levels
(Rutka et al. 1998; Strojnik et al. 2007; Skalli et al. 2013), the results of Sultana
et al (1998) suggest that in astrocytoma cells, expression of GFAP, but not
vimentin and nestin, is regulated by factors binding to tyrosine kinase receptors
and some extracellular matrix proteins (Sultana et al. 1998).
Altogether, these studies show that factors, such as retinoids, tyrosine
kinase receptor binding growth factors, histone deacetylase inhibitors, and notch
signaling can regulate IF protein expression. However, a given regulatory agent
may have opposing effects on the expression of the different types of IF proteins
in a particular cell. Also, a given regulatory agent can differentially modulate
expression of a particular IF protein in a cell type specific manner.
Similar to other IF proteins, synemin is regulated during development and
in cancer (see section 1.4.2 of the Chapter 1 for details). However, to our
knowledge, factors regulating expression level of synemin isoforms have yet to
be identified. Obtaining information about these factors is important to better
understand the roles of synemin in cells and its relation to particular signaling
pathways.
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This prompted us to undertake studies to identify exogenous modulators
of synemin expression in cancer cell lines of different lineages, including human
astrocytoma cells (U373-MG), human cervical carcinoma cells (HeLa) and
mouse neuroblastoma cells (N2a) cells. Initial Western blot and reverse
transcriptase-PCR (RT-PCR) experiments demonstrated that all these cell lines
express the three synemin isoforms. For these experiments, the cells were
cultured in DMEM supplemented with either insulin, transferrin and selenium
(ITS) or with 1% FCS. The cells were then treated with compounds known to
affect the expression level of IF proteins other than synemin, including TGF-,
the notch pathway inhibitor -secretase inhibitor 1 (GSI-1) and all-trans retinoic
acid (ATRA). Changes in synemin protein levels in response to these exogenous
treatments were quantified by densitometric analysis of western blots.
2.2 Material and Methods
2.2.1 Growth factors
Human recombinant TGF-(Gibco, Carlsbad, CA) was reconstituted in
sterile water to a final concentration of 10 ng/l. GSI-1 (Calbiochem, Billerica,
MA) was reconstituted in DMSO to a final concentration of 500 M. ATRA
(Sigma, St. Louis, MO) was reconstituted in DMSO to a final concentration of 10
mM.
2.2.2 Culture conditions
U373-MG human glioblastoma cells and HeLa human cervical carcinoma
cells were obtained from American Type Culture Collection (ATCC, Rockville,
MD). Mouse N2a neuroblastoma cells were a kind gift from Dr. Ramin
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Homayouni (Department of Biological Science, University of Memphis, Memphis,
TN). All cells were plated in Dulbecco’s modified Eagles medium (DMEM)
(Invitrogen) containing 10% fetal calf serum (FCS) (Invitrogen) and 100 U/ml
penicillin and 100 g/ml streptomycin (PS) (Lonza, Walkersville, MD).
U373-MG and HeLa cells were plated at a density of 1.2x104 cells/cm2
and N2a cells, which have a rapid doubling time, were plated at a much lower
density of 3x103 cells/cm2. Since the cells were incubated with exogenous agents
for 3-5 days, plating cells at a low density helped to minimize the effects of cellcell contact on differentiation of these cells.
The day after plating the medium was replaced with serum-free DMEM
supplemented with PS and insulin (10 g/ml final), transferrin (5.5 g/ml final)
and selenium (7 ng/ml final) (ITS) (Gibco, Carlsbad, CA) (serum-free medium) for
U373-MG and HeLa cells or with DMEM supplemented with PS and 1% FCS
(low serum medium) for N2a cells. After incubating the cells in serum free or low
serum media overnight, TGF- (10 ng/ml) or GSI-1 (1M) was added to the
culture medium and an equal volume of vehicle was added to control dishes.
Cells were grown in the presence of TGF- and GSI-1 for three days and then
processed for Western blotting.
For treatment of U373-MG and HeLa cells with ATRA, 5M ATRA was
added the day after plating to the DMEM supplemented with 10% FCS. For N2a
cells, the medium was replaced the day after plating with DMEM supplemented
with 1% FCS, PS and 5μM ATRA. An equal volume of vehicle was added to
control dishes. All cells were treated with ATRA for 5 days during which medium
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was changed and replenished with ATRA or vehicle after every two days. After
the 5 day treatment period the cells were processed for Western blotting.
2.2.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
For RT-PCR, total RNA was purified from all tumor cells with the High
Pure RNA Isolation kit (Roche, Indianapolis, IN) and treated with RNase-free
DNase I to remove potential genomic DNA contamination. cDNA synthesis and
synemin cDNA amplification were performed with the One-Step Titanium RTPCR kit (Clontech, Mountain View, CA) following manufacturer’s instructions and
using as template 100 ng of total RNA for N2a cells and 50 ng of total RNA from
U373-MG and HeLa cells.
Amplification of a 1310 bp mouse L-synemin cDNA fragment from N2a
cells RNA was conducted using 5’-CACAAGATGGATTTGAGCGACACG-3’ and
5’-CGCCATTGCCACTTCATAACTGT-3’ as forward and reverse primers,
respectively. Thermocycling included 30 cycles of 94ºC for 30 seconds, 56ºC for
30 seconds and 68ºC for 1 minute and 20 seconds.
Amplification of a 967 bp human L-synemin cDNA fragment from
U373-MG and HeLa cells was conducted using
5’-CATGCCGTCAGATGGATGTGAGTAA-3’ and
5’-CTACAGCTGTCCTCGCCATAAA-3’ as the forward and reverse primers,
respectively. Thermocycling included 30 cycles of 94ºC for 30 seconds, 54ºC for
30 seconds and 68ºC for 1 minute. PCR DNA products were analyzed by
electrophoresis on 0.8 % agarose gels using standard protocol.
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2.2.4 Western blotting
Comparison of synemin levels was done by Western blotting with cells
lysates prepared in Laemmli sample buffer (Laemmli. 1970). The total protein
concentration of the lysates was determined with the bicinchoninic acid (BCA)
reagent (Pierce, Rockford, IL) as previously described (Smith et al. 1985). Gel
electrophoresis was then performed with 2 μg of total cellular proteins loaded
onto the lanes of 4-15% SDS-polyacrylamide gradient gels (Biorad, Hercules,
CA). The electrophoretic separation of proteins was performed at a constant
voltage of 200 V for 30 minutes. After electrophoresis, the proteins separated in
the gel were transferred onto nitrocellulose membranes at a constant voltage of
100 V for 1 hour.
After the transfer, the nitrocellulose blots were incubated for 1 hour in 5%
milk in PBS (PBS-milk) to block non-specific binding sites. Next, the blots were
incubated for 1 hour at room temperature with primary antibodies diluted in PBSmilk as follows: 1:250 for affinity-purified rabbit anti-synemin (Jing et al. 2005)
and 1:500 for rabbit anti-actin (Skalli et al. 1986). The blots were then washed
with PBS three times for 5 minutes each. Next, the blots were incubated for 1
hour at room temperature in the appropriate secondary antibody conjugated to
horseradish peroxidase (Jackson Immunoresearch, West Grove, PA) and diluted
1:500 in PBS-milk. At the end of the incubation, the blots were washed with PBS
three times for 5 minutes each. The peroxidase activity was detected with by a
colorimetric reaction using tetramethylbenzidine as a substrate (Kirkegaard &
Perry, Gaithersburg, MD).
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Quantification of synemin protein levels between control and treated cells
was performed by densitometry of Western blots using the U-SCAN IT gel
Analysis Software (Silk Scientific Inc, Orem, UT). The density of the actin band
was used to normalize the data between lanes. For each condition, the values of
three or more independent experiments were used to calculate means ± SEM.
Statistical analysis of the data was performed using Student’s t-test performed
with QuickCalcs software (GraphPad, La Jolla, CA).
2.3 Results
2.3.1 mRNA and Protein Expression of Synemin Isoforms in U373-MG, HeLa
and N2a Cells.
First, we examined whether the composition of the synemin isoforms
differed between the three cell lines examined. The expression of - and synemin was examined with antibodies (Jing et al. 2005). However, these
antibodies do not recognize L-synemin because these antibodies were raised
against the C-terminal region of -synemin. This region is identical to the Cterminal of -synemin, with the exception of a 312 amino acid sequence that is
missing in -synemin. L-synemin, however, lacks this C-terminal domain (see
Introduction 1.4.1) and thus, is not recognized by these antibodies. Therefore,
while - and -synemin expression was probed by Western blot, L-synemin
expression was investigated by RT-PCR.
Western blotting demonstrated that U373-MG, HeLa and N2a cells
express - and - synemin (Figure 2.1 A). Interestingly, the ratio of  to 
synemin substantially differed between the three cell types examined. Thus,
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while N2a cells have similar protein levels of  and  synemin (/ = 1.3 ± 0.1),
in U373-MG cells  synemin is expressed at higher levels than -synemin (/ =
2.4 ± 0.5). The predominance of - synemin over -synemin is even more
pronounced in HeLa cells (/ = 7.18 ± 1.02). RT-PCR revealed the presence of
L-synemin in the three cell lines examined (Figure 2.1 B). The size of the
amplified L-synemin cDNA fragment in N2a cells was 1.3 kb whereas it was 0.9
kb in U373-MG and Hela cells (Figure 2.1B). This size difference is due to the
fact that the N2a cells are of murine origin, whereas U373-MG and HeLa cells
are of human origin and that there are species-specific differences in the size of
L-synemin.

Figure 2.1 Expression of synemin isoforms in U373-MG, HeLa, and N2a cells. (A) Western
blot analysis demonstrates that U373-MG, HeLa and N2a cells express - and -synemin but at
different / ratios. (B) RT-PCR shows that L-synemin is present in all three cell lines as a 967 bp
L-synemin cDNA fragment is amplified from total RNA purified from U373-MG and HeLa cells and
a 1310 bp L-synemin cDNA is amplified from total RNA purified from N2a cells.
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2.3.2. Effects of TGF-, GSI-1 and ATRA on the Morphology of U373-MG,
HeLa and N2a Tumor Cells
U373-MG cells when grown in the presence of serum have a polygonal
morphology, large leading edge, and rare cytoplasmic processes. In ITS medium,
these cells have small rounded cell bodies with long cytoplasmic processes
(Figure 2.2 A, 2.3 A, and 2.4 A). HeLa cells, on the other hand, are flat,
irregularly rounded cells that tend to grow in clusters. These cells do not show
morphological changes when grown in ITS medium (Figure 2.2 C, 2.3 C, and 2.4
C). Undifferentiated N2a cells have a round morphology and form clusters when
grown in vitro in medium containing 10% serum (data not shown). Under these
conditions, few N2a cells have processes. In low serum medium, however, N2a
cells appear to extend small cytoplasmic processes (Figure 2.2 E, 2.3 E, and 2.4
E) (Evangelopoulos, Weis, and Krüttgen. 2005). We did not notice any obvious
change in the shape of U373-MG, HeLa or N2a cells after treating with TGF-
when compared to control cells (Figure 2.2 B, D, and F). TGF- however, did
cause HeLa cells to proliferate much faster than control cells (Figure 2.2 C and
D). This increased proliferation was not observed in U373-MG or N2a cells
treated by TGF- (Figure 2.2 A, B, E, and F). However, since cell counts were
not performed, we cannot exclude that a small change in proliferation did occur in
these cell lines.
GSI-1 did not induce any obvious morphological changes in U373-MG or
HeLa cells (Figure 2.3 A, B, C and D). However, N2a cells treated with GSI-1
became less rounded and more spindle-shaped, extended longer neurites, and
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show very little proliferation when compared to cells growing in low serum
medium and treated with vehicle (Figure 2.3 E and F). There was no gross
change in the proliferation of U373-MG or HeLa following GSI-1 treatment.
U373-MG, HeLa and N2a cells also respond very differently to ATRA
treatment. When treating with ATRA, U373-MG and HeLa cells were cultured in
medium containing 10% FCS. This is because when ATRA was added to these
cells in ITS supplemented DMEM, it caused the cells to round up and detach
from the substratum. This, however, did not happen when ATRA was added to
U373-MG and HeLa cells grown in medium containing 10% FCS. Under these
conditions, the cells did not exhibit any obvious changes in attachment,
morphology or proliferation rates when compared to vehicle treated cells (Figure
2.4 A, B, C and D). In the case of N2a cells, the addition of ATRA to cells grown
in low serum medium causes them to extend neurites, take on a neuron-like
appearance, and have reduced proliferation when compared to control cells
growing in low serum medium and treated with vehicle (Figure 2.4 E and F).
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Figure 2.2 Morphology of U373-MG (A, B), HeLa (C, D), and N2a (E, F) cells after treating
with TGF-. Phase contrast micrograph of control (A, C and E) and 3 day TGF- treated (B, D,
and F) U373-MG, HeLa and N2a cell cultures. Bar= 100M
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Figure 2.3 Morphology of U373-MG (A, B), HeLa (C, D), and N2a (E, F) cells after treating
with GSI-1. Phase contrast micrograph of control (A, C and E) and 3 day GSI-1 treated (B, D,
and F) U373-MG, HeLa and N2a cell cultures. Bar= 100M
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Figure 2.4 Morphology of U373-MG (A, B), HeLa (C, D), and N2a (E, F) cells after treating
with ATRA. Phase contrast micrograph of control (A, C and E) and 5 day ATRA treated (B, D,
and F) U373-MG, HeLa and N2a cell cultures. Bar= 100M
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2.3.3 Treatment with TGF-, GSI-1 and ATRA differentially regulate - and 
synemin levels in U373-MG, HeLa and N2a cells.
Densitometric analysis of Western blots demonstrated that TGF- had
opposite effects on synemin levels in U373-MG and HeLa cells (Figure 2.5).
While in U373-MG cells TGF- increased -synemin by 26% (p= 0.0489) without
significantly affecting the levels of -synemin (p= 0.937), in HeLa cells, TGF-
reduced - and -synemin protein levels by 42% (p= 0.0002) and 90% (p=
0.0001), respectively (Figure 2.5). TGF-, however, did not significantly affect and -synemin protein levels in N2a cells (Figure 2.5).
Inhibiting the notch signaling pathway by GSI-1 significantly affected
synemin levels in N2a cells, but not in U373 and HeLa cells (Figure 2.6). In N2a
cells, GSI-1 decreased - and -synemin protein levels by 53% (p=0.0043) and
60% (p=0.01), respectively.
ATRA did not significantly alter synemin levels in U373-MG cells, but
significantly decreased - and -synemin both in HeLa and N2a cells (Figure
2.7). Thus, in HeLa cells, ATRA decreased - and - synemin by 56% (p=
0.0007) and 78% (p= 0.009), respectively (Figure 2.7) while in N2a cells, ATRA
reduced - and -synemin by 59% (p= 0.0008) and 50% (p= 0.0001),
respectively (Figure 2.7).
In U373-MG cells, the ratio of  and  synemin did not change significantly
between control and any of the three treatment groups. In HeLa cells, there was
a significant increase in the ratio of  and  synemin levels between control and
cells treated with TGF-(p= 0.0001) and ATRA (p= 0.0009). In N2a cells, the
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ratio of  and  synemin levels was significantly increased by GSI-1 (p= 0.03)
and ATRA (0.013) treatments, respectively.

Figure 2.5: Effect of TGF- on protein levels of synemin in U373-MG, HeLa, and N2a cells.
(A): Western blot showing the effect of TGF- on synemin levels in U373-MG, HeLa and N2a
tumor cells. The lanes labeled “control” shows the result for the control sample. Lanes adjoining
the control show result for cells treated with 10 ng/ml TGF-. Actin was used as a loading control
in these experiments. (B): Histogram showing the changes in -synemin (SA) and -synemin
(SB) levels in the three cell lines. Values were calculated from three independent experiments
and expressed as means ± SEM.
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Figure 2.6: Effect of GSI-1 on synemin protein levels in U373-MG, HeLa, and N2a cells. (A):
Western blot showing the effect of GSI-1 on synemin levels in U373-MG, HeLa and N2a cells.
The lanes labeled “control” shows the result for the control sample. Lanes adjoining the control
show result for the cells treated with 1M GSI-1. Actin was used as a loading control for these
experiments. (B): Histogram showing the changes in -synemin (SA) and -synemin (SB) levels
in the three cell lines. Values were calculated from three independent experiments and are
expressed as means ± SEM.
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Figure 2.7: Effect of ATRA on synemin protein levels in U373-MG, HeLa, and N2a cells. (A):
Western blot showing the effect of ATRA on synemin levels in U373-MG, HeLa and N2a tumor
cells. The lanes labeled “control” shows the result for the control sample. Lanes adjoining the
control show result for the cells treated with 5M ATRA. Actin was used as a loading control in
these experiments. (B): Histogram showing the change in -synemin (SA) and -synemin (SB)
levels in the three tumor cell lines. Values were calculated from at least three independent
experiments and expressed as means ± SEM.
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2.4 Discussion
Synemin expression is regulated during development and in pathologic
conditions (Sultana et al. 2000; Izmiryan et al. 2009; Jing et al. 2005). For
instance, synemin is not present in normal mature astrocytes, but becomes
expressed during the malignant transformation of these cells into astrocytomas
(Jing et al. 2005; Skalli et al. 2013). While synemin has been shown to be
important in determining the motility and proliferation of astrocytoma cells (Pan et
al. 2008; Pitre et al. 2012), little is known about the factors and/or pathways
involved in regulating synemin levels during the malignant transformation of cells.
The results of our present investigations reveal new facts regarding the
expression of synemin isoforms and the potential regulation of their levels in
different tumor cell types. Our studies demonstrate that astrocytoma, carcinoma,
and neuroblastoma cells express all three synemin isoforms, namely, , , and Lsynemin. Although, expression of  and  synemin has been documented in
U373-MG and HeLa cells (Jing et al. 2005; Hirako et al. 2003), our study is the
first to document the expression of L-synemin in these cells. As for the
expression of synemin isoforms in N2a cells, to our knowledge, this is the first
report showing that synemin is expressed in a neuronal tumor cell line. In
addition, our results also show that the levels of  and  synemin, and
consequently, the ratio of these two isoforms, are different in different tumor cell
lines. We were unable to determine if L-synemin protein levels were different in
these tumor cells because of the lack of antibodies against this protein. In any
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event, the difference in the / synemin ratio between the different tumor cell
lines is suggestive of functional differences between these isoforms.
Our results also demonstrate that  and -synemin can be regulated by
different signaling pathways in a manner that is dependent on the cellular
context. In astrocytomas, only TGF- regulated synemin levels, and not GSI-1 or
ATRA. The effect of TGF- on synemin levels in an astrocytoma cell line may be
physiologically relevant because TGF- is often overexpressed in astrocytoma
tumors where it binds to the epidermal growth factor receptor (EGFR) expressed
on the tumor cells to generate an autocrine/paracrine loop that maybe
instrumental in malignant transformation of astrocytes (Maxwell et al. 1991).
TGF- mediates its biological effects by binding to the EGFR and
activating signaling pathways regulating cell proliferation and motility (Hatanpaa
et al. 2010). Previous work from our laboratory has shown that synemin regulates
astrocytoma proliferation (Pitre et al. 2012; Pan et al. 2008). Taken together,
these results suggest that one of the effects of the binding of TGF- to the EGFR
is to increase synemin levels in astrocytoma cells and that this contributes to
increase the proliferation of these cells by antagonizing PP2A activity, as shown
by Pitre et al. (2012).
Compared to normal astrocytes, astrocytoma cells contain low GFAP, high
nestin, and high synemin (Skalli et al. 2013). Previous findings from our
laboratory showed that TGF- decreases GFAP levels and increases nestin
levels in astrocytoma cells (Sultana et al. 1998; Zhou and Skalli. 2000). Together
with our finding that TGF- also upregulates synemin in astrocytoma cells, these
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findings establish TGF- as a key regulator of the IF protein composition of
astrocytoma cells.
Synemin, however, is not regulated in the same manner in HeLa
carcinoma cells and in N2a neuroblastoma cells. While TGF- shows no
significant effect on synemin levels in N2a cells, in HeLa cells TGF- decreases
synemin levels in an isoform specific manner (the decrease in -synemin is less
than -synemin), at the same time it increases cell proliferation. This is in
contrast to astrocytoma cells, where synemin upregulation is associated with the
proliferative capacity of these cells (Pan et al. 2008; Pitre et al. 2012). This may
be due to the differences in the mutations responsible for tumorigenesis in
astrocytoma cells and in HeLa cells and/or to the possibility that synemin roles in
cells is regulated by the ratio of / synemin.
Synemin regulation in HeLa and N2a cells also differs from astrocytoma
cells since ATRA downregulates synemin in HeLa and N2a cells, but does not
significantly affect synemin levels in U373 astrocytoma cells. ATRA, a vitamin A
metabolite and a known differentiating agent, binds to nuclear retinoic acid
receptors (RARs) and the retinoid X receptors (RXRs) to orchestrate patterning
of the nervous system during early development (Clagett‐Dame, McNeill, and
Muley. 2006). ATRA is also a key regulator of epithelial cell differentiation
(Borutinskaite, Navakauskiene, and MAGNUSSON. 2006). Synemin is present in
neuronal precursor cells but not in differentiated neurons, and is also absent in
differentiated epithelial cells. Therefore, our results that ATRA decreases
synemin levels in HeLa and N2a cells suggest that this change is linked to the
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fact that ATRA induces a progressively differentiated phenotype in these cells
(Canon et al. 2004; Guo et al. 2006).
Inhibition of Notch signaling with GSI-1 downregulated synemin in N2a
neuroblastoma cells but did not significantly alter synemin levels in U373 and
HeLa cells. The effect of GSI-1 on synemin in N2a cells may be due to the fact
that inhibiting Notch induces these cells to progress towards a more
differentiated phenotype, which is characterized by low synemin levels (Izmiryan
et al. 2010). Several lines of evidence point to a role of notch inhibitors in the
progression of neuroblastoma cells toward a more differentiated phenotype.
Franklin et al. (1999) showed that inhibition of the notch pathway, by preventing
Notch 1 receptor from binding to its Delta 1 and Jagged 1 ligand, causes
neuroblastoma cells to extend longer primary neurites (Franklin et al. 1999; Zhou
et al. 2010). Similarly, Lassiter et al. (2010) showed that inhibiting notch signaling
by a -secretase inhibitor increased differentiation of sensory neurons (Lassiter et
al. 2010).
Except for mature muscle cells, synemin is expressed mainly in progenitor
cells, as in the case of neuronal and glia precursor cells (Sultana et al. 2000;
Izmiryan et al. 2009). Therefore, it is logical to expect that agents affecting
pathways regulating cell differentiation will alter synemin levels and that this
effect will depend on cell lineage.
The ratio of  and  synemin increases in HeLa cells after TGF- and
ATRA treatment and in N2a cells after GSI-1 and ATRA treatment. It remains to
be seen how change in the synemin isoforms composition may affect cellular
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behavior in different cell types. That these changes may be relevant in specifying
different cellular behavior is suggested by the case of peripherin, another IF
protein with multiple isoforms. Change in ratio of peripherin isoforms Per-58 and
Per-45 have been shown to be relevant to the pathology of amyotrophic lateral
sclerosis (McLean and Robertson. 2011). Similarly, it was shown that shifting the
ratio of isoforms of GFAP, another IF protein that has several splice variants, in
astrocytoma cells regulates the interaction of astrocytoma cells with the
extracellular matrix through laminin and affects cell motility (Moeton et al. 2014).
Altogether, the results in this chapter identify factors that regulate synemin
expression levels in cancer cells (Table 2.1). They show that TGF-, a factor that
increases the malignant behavior of astrocytoma cells, also increases synemin
levels in these cells. Thus, TGF- may play a role in the induction of synemin
which occurs during the malignant transformation of astrocytes. However, TGF-
does not appear to play a role in upregulating synemin in malignant epithelial
cells and peripheral neuronal cells. In malignant peripheral neuronal cells, we
show that two factors that are known to induce the differentiation of these cells,
ATRA and GSI-1, cause a decrease in synemin expression. This suggests that
retinoid and notch pathways may be responsible for the decrease in synemin
expression that occurs during the differentiation of peripheral neurons.
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Table 2.1: Summary of the effect of various exogenous agents on the level of synemin in
different tumor cells.
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Chapter 3: Use of Proximity Ligation Assay to Study Synemin Interaction
with Cellular Proteins
3.1 Introduction
Our goal in Chapter 2 was to identify the factors that regulate synemin
expression in cancer cell lines derived from different tissues. These experiments
provided information about signaling pathways that control synemin activity and
function in these cells. In this chapter, our aim was to gain additional knowledge
about the proteins with which synemin interacts in tumor cells to have a better
understanding of the function of synemin in these cells. Previously, studies from
our laboratory have used immunoprecipitation to demonstrate that in astrocytoma
cells synemin forms complexes with -actinin (Jing et al. 2005) and PP2A (Pitre
et al. 2012). Immunoprecipitation was also used by other laboratories to
demonstrate that in different contexts, synemin also binds to vimentin (Bellin et
al. 2001), vinculin (Bellin et al. 2001; Sun et al. 2008), metavinculin (Sun et al.
2008), dystrobrevin (Mizuno et al. 2001), dystrophin (Bhosle et al. 2006) and with
the regulatory subunit RIIa of PKA (Russell et al. 2006).
The synemin binding proteins identified by immunoprecipitation were also
validated by other methods, including yeast two-hybrid screening for vinculin
(Bellin et al. 1999) and -actinin (Bellin et al. 1999; Bellin et al. 2001) and blot
overlay assays with purified proteins to determine synemin interaction with actinin, desmin and keratin (Bellin et al. 1999; Hirako et al. 2003). In addition,
incorporation of synemin into desmin, vimentin or GFAP IFs was examined by
co-sedimentation assays (Bellin et al. 1999; Jing et al. 2007). In these assays,
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purified synemin was mixed with vimentin, desmin or GFAP in buffers of ionic
strength that were either favorable or unfavorable to filament formation. The
protein mixtures were then subjected to high-speed centrifugation to determine
whether synemin sediments with desmin, vimentin or GFAP IF proteins.
While immunoprecipitation is a widely used technique to study proteinprotein interactions in general, it does suffer drawbacks when used to identify the
interacting partners for IF proteins, including synemin. This is because in most
cells, 80%-90% of the pool of IF proteins are insoluble in immunoprecipitation
lysis buffers (Soellner, Quinlan, and Franke. 1985). The buffers used in
immunoprecipitation experiments usually have physiological pH and ionic
strength, contain a non-ionic detergent, such as NP40, and protease inhibitors.
Cell lysates prepared in such buffers are then centrifuged at 5,000xg or higher for
10 minutes to sediment the insoluble cellular components. Following
centrifugation, the pellet, which contains the majority of the cell’s IF proteins, is
discarded and the supernatant is used in the subsequent steps of the
immunoprecipitation procedure. Therefore, during immunoprecipitation the bulk
of the cellular IF proteins is discarded because it is present in the pellet rather
than in supernatant. Hence, immunoprecipitation cannot be used as a standalone
technique to identify interacting partners of polymerized IF proteins. In addition, a
more general drawback of immunoprecipitation procedures is that they do not
provide information about the subcellular locations where protein interactions
occur.

61

To circumvent these two major limitations of immunoprecipitation, different
techniques have been developed, including Förster Resonance Energy Transfer
(FRET) (Kenworthy. 2001), Bimolecular Fluorescence Complementation Assay
(BiFC) (Kerppola. 2006) and Proximity Ligation Assay (PLA) (Smith et al. 2015).
FRET and BiFC are very sensitive techniques that allow visualization of proteinprotein interactions in live cells. However, these procedures can be technically
challenging and require the overexpression of fusion proteins. Therefore, FRET
and BiFC may yield results that may not truly reflect how native proteins interact
at physiological concentrations. On the other hand, PLA, albeit carried out on
fixed cells, enables visualization and quantification of protein interactions in-situ
without expressing tagged proteins. Moreover, compared to FRET and BiFC,
PLA is a relatively simple technique that generates discreet fluorescent signals
which are easily quantifiable using standard image processing software. Briefly,
PLA utilizes antibodies specific for two proteins of interest along with DNA
amplification to determine whether these two proteins are in close proximity (<
30nm). A more detailed description of the PLA procedure will be given in section
3.2 below. PLA enables detection of protein-protein interactions even between
proteins that are insoluble in immunoprecipitation lysis buffer and facilitates the
subcellular localization of these interactions. Therefore, as synemin is mostly
insoluble in the immunoprecipitation lysis buffer (Jing et al. 2005) PLA represents
an attractive alternative to immunoprecipitation for the identification of synemin
binding partners.
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PLA is extremely sensitive and a fairly recently developed technique.
Therefore, to evaluate the potential utility of PLA to identify novel synemin
binding partners, we initiated a systematic series of experiments to define the
conditions and the controls needed to assess the specificity of PLA results. The
outcome of the experiments performed to optimize the PLA technique to study
the interaction of synemin with cellular proteins was published in Methods of
Enzymology (2016, vol. 568, 537-555) under the title: “Synemin: Molecular
Features and the Use of Proximity Ligation Assay to Study its Interactions” (Paul
and Skalli. 2016). The text of the publication is included below with the exception
of the introduction, because it contains information on synemin that has been
presented in the introduction of this dissertation.
3.2 Proximal Ligation Assays (PLA) for In-situ Detection of Synemin
Interaction with Binding Partners
The first step of PLA is the incubation of the cells with primary antibodies
against synemin and a potential interacting partner and then with appropriate
secondary antibodies each conjugated to oligonucleotides with a unique
sequence (Figure 3.1). Next, cells are incubated with two circle-forming DNA
oligonucleotides in the presence of a ligase. If the nucleotides attached to each
of the secondary antibodies are in close proximity (less than 40 nm apart)
(Zatloukal et al. 2014; Trifilieff et al. 2011), they will hybridize with the two circleforming DNA oligonucleotides and the ligase will catalyze formation of a closed
circle (Figure 3.1). An amplification step is then performed in which the
oligonucleotide arm of one of the secondary antibodies serves as primer for a
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rolling circle amplification reaction catalyzed by a polymerase and using the
closed circle as template. This generates a long concatemeric copy of the closed
DNA circle formed during the ligation reaction (Figure 3.1). During amplification,
fluorescently labeled oligonucleotides complementary to a tag sequence on the
concatemer hybridize with the concatemer to generate fluorescent dots that can
be imaged with a fluorescence microscope. The presence of such fluorescent
dots indicates that synemin and the protein tested are close by, either because
they bind directly to each other or because they are separated by a short
distance in a multiprotein complex.
Probes and reagents to perform PLA can be obtained from Sigma Inc. (St.
Louis, MO) either individually or as the Duolink In Situ Detection Reagent kit. The
manufacturer provides information about some of the buffers comprised in the kit.
This includes buffer A (1x): 0.01M Tris, 0.15 M NaCl and 0.05% Tween 20, pH
7.4, and buffer B (1x): 0.2 M Tris and 0.1 M NaCl, pH 7.5. Both solutions should
be filtered through a 0.22 m filter and stored at 4°C. In addition, the ligation and
amplification reaction reagents can be prepared as described by (Jarvius et al.
2007) and (Söderberg et al. 2006). While the manufacturer does not disclose the
composition of the blocking solution and antibody diluent included in the kit,
some laboratories prepare their own (Jarvius et al. 2007; Söderberg et al. 2006).
Finally, users can custom design their PLA probes by conjugating amine
modified oligonucleotides (Jarvius et al. 2007; Söderberg et al. 2006) to
secondary antibodies of their choice with the Duolink Probemaker kit (Sigma Co.
St. Louis, MO).
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Figure 3.1: Diagram showing the different steps of a PLA. (A) Micrograph of U87 cells
transfected with -synemin, processed for PLA with anti-synemin and anti-PP2A (red dots) and
counterstained for synemin (green filamentous network). (B) In panels 1-6, synemin is
represented by green filaments and PP2A by its A, B, and C subunits. Panel 1 shows the
proximity of synemin with PP2A. Panel 2: the first step of the PLA reaction is the incubation of
fixed and permeabilized cells with primary antibodies against synemin and PP2A A subunit. Panel
3: next, cells are incubated with secondary antibodies (PLA probes PLUS and MINUS)
conjugated to oligonucleotides. Panel 4: ligation step in which connector oligonucleotides (in
brown) and ligase are added to the cells to ligate the oligonucleotides attached to the PLA probes
into a circular structure. Panel 5: following ligation, amplification solution is added to the cells to
initiate rolling circle amplification using oligonucleotide attached to one of the PLA probes as
primer. Fluorescently labelled oligonucleotides (red) hybridize to complementary tag sequences
in the amplified product (orange). The PLA probe that is not used for amplification has a blocked
2’-O-methyl RNA (filled purple circle) in the 3’ end of its conjugated oligonucleotide. Panel 6: cells
are counterstained with fluorescently labelled secondary antibody (*green) directed against the
anti-synemin primary antibody.
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3.2.1. Choosing primary antibodies and optimizing their dilutions
Similar to double immunofluorescence, the two primary antibodies used
for PLA must be raised in two different species. In addition, it is critical to first
control the specificity of these antibodies and their suitability for immunostaining
and then to optimize their dilution before proceeding to PLA.
Step 1. Verifying antibody specificity
To obtain reliable PLA information it is essential to first evaluate the
specificity of the primary antibodies by Western blotting even if the antibodies
manufacturer claim that they are highly specific. These experiments should
demonstrate that, in cell type(s) in which PLA is to be performed, the antibodies
strongly label their target antigens and do not recognize any other proteins.
Antibodies failing to demonstrate specificity should not be used for PLA as they
may generate false positive signals by recognizing proteins other than those of
interest.
Step 2. Verifying antibody suitability for immunostaining
After validation of the specificity of the primaries, double
immunofluorescence staining of the cell type(s) to be used for PLA is performed
to evaluate whether both primaries bind to their respective antigen under the
same set of fixation and permeabilization conditions. After permeabilization,
perform a 30 minute blocking step at 37ºC in a humid chamber using the PLA
blocking buffer provided by the manufacturer. All antibodies should be diluted in
PLA diluent provided by the manufacturer. This will ensure that the blocking
agents included in blocking and dilution buffers do not interfere with antibody
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binding and/or cause background artifacts. Antibody pairs yielding the expected
staining patterns under these conditions are acceptable for PLA.
Step 3. Optimizing antibody dilutions
PLA is much more sensitive than immunofluorescence due to the rolling
circle amplification step. Thus, dilutions of primary antibodies for PLA should
generally be higher than those for immunofluorescence to avoid background
and/or false positive signals.
Each primary antibody should be optimized separately for PLA. This is
done by using the fixation, permeabilization, and blocking conditions working for
immunofluorescence staining, but with a dilution range of the primary antibody
spanning from 10 to 200 times the dilution for immunofluorescence staining. For
instance, with a primary antibody diluted at 1:50 for immunofluorescence, PLA
dilutions of 1:500, 1:1000, 1:2000, 1:4000, 1:8000 and 1:16000 should be tested.
The goal of this titration is to determine the dilution at which the PLA signal is
extinguished and then to use half that dilution for the PLA experiment. For
instance, if no or very few PLA fluorescent products are observed at 1:8,000, the
primary antibody should be diluted at 1:4,000 in the actual experiment.
After incubation with the primary, the PLA procedure described below is
followed. In this instance, the two secondary PLA probes used are conjugated to
the minus and plus oligonucleotides and are against IgGs of the species in which
the primary antibody was produced. Using the dilution determined for the
primary, it is also useful to test three dilutions of the secondary, including 1:5
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(recommended by the manufacturer), 1:10, and 1:20 and to choose the dilution
that result in less than 200 dots per cell.
3.2.2 Performing the PLA reaction
Unless otherwise stated, all the steps are carried out at room temperature
(20-25˚C).
1. Grow cells of interest in appropriate culture medium on No. 1.5 sterile
cover glasses.
2. On the day of the experiment, use fine point jeweler forceps to lift the
coverglasses off the wells. Briefly wash coverglasses by gently dipping in and out
a 100 ml beaker containing 70 ml PBS. From this point on, keep track of the side
of the cover glass onto which the cells are attached.
3. Transfer cover glasses to a cover glass staining jar (Electron
Microscopy Sciences, cat # 72242-21) containing 4% formaldehyde in PBS
(diluted from 20% paraformaldehyde solution, Tousimis, cat # 1008A). Fix for 5
minutes.
4. Transfer cover glasses to a staining jar containing PBS and let sit 5
minutes.
5. Transfer cover glasses to a staining jar containing 0.1% NP-40 or
Triton-X-100 (v/v PBS) and incubate for 5 minutes. This solubilizes the plasma
membrane and enables antibodies and other reagents to enter the cell interior in
subsequent steps.
6. Transfer cover glasses to a staining jar containing PBS and let sit 5
minutes.
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7. In a humid chamber, lay coverglasses flat, cells facing up and place 40
l/cm2 blocking buffer on the cells. Incubate for 30 minutes at 37°C.
8. Rinse off blocking buffer by dipping coverglass 2-3 times in a beaker
containing PBS.
9. Return cover glasses to the humid chamber and place 40 l/cm2 of the
two primary antibodies diluted in dilution buffer at the dilution determined in
preliminary experiments. Incubate for 1 hour at room temperature.
10. Tap off the primary antibodies solution from the cover glasses and
rinse them 2x5 minutes with wash buffer A included in the PLA kit.
11. Return cover glasses to the humid chamber, place 40 l/cm2 of
complementary PLA probes diluted in dilution buffer at the dilution determined in
preliminary experiments. Incubate for 1 hour at 37°C.
Choice of the PLA probes: for instance, if one of the primaries was raised
in rabbit and the other in mice, the PLA probes should be donkey-anti-mouse IgG
Plus probe and donkey anti-rabbit IgG Minus probe. The opposite combination of
probes (donkey-anti-mouse IgG Minus probe and donkey anti-rabbit IgG Plus
probe) would work as well.
12. Tap off the PLA probe solution and rinse cover glasses 2x5 minutes
with wash buffer A.
13. Return cover glasses to the humid chamber and incubate for 30
minutes at 37°C with 40 l/cm2 of ligase diluted 1:40 in ligation buffer provided by
the manufacturer.
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14. Tap off ligation solution off the cover glasses and wash them in 1x
wash buffer A for 2x2 minutes.
15. Return cover glasses to the humid chamber and incubate for 100
minutes at 37°C with 40 l/cm2 of polymerase diluted 1:80 in amplification
solution provided by the manufacturer.
17. Tap off amplification solution from the cover glasses and wash them in
1x wash buffer B (provided by the manufacturer) for 2x10 minutes.
18. Perform a 1 minute high-stringency wash in 0.01x wash buffer B.
19. At this stage, a counterstaining step can be performed. This can be
done, for instance, by incubating the cells for 10 min at room temperature with
fluorescently labelled phalloidin diluted 1:100 in PBS, or with a 1:50 dilution (in
PBS) of a fluorescently labelled secondary antibody against one of the primaries
(Figure 2). The fluorescent conjugate attached to the antibody or phalloidin must
emit light of a different wavelength than the fluorescent PLA dots. After this
counterstaining step, wash cells 2x2 minutes in PBS.
20. Without allowing the cells to dry, mount cover glasses with Prolong
Diamond Antifade with or without DAPI (Molecular Probes) and let the mounting
medium harden overnight. Alternatively, cover glasses can be mounted using
Duolink II mounting medium with DAPI.
21. Observe the cells with a wide field fluorescent microscope rather than
with a confocal scanning laser microscope (CSLM). Alternatively, use a CSLM to
obtain optical sections z-stacks and make sure to use settings such that these
sections will cover most of the cell volume. This will enable observation of PLA
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dots present throughout entire cytoplasmic volume, which is especially important
when carrying out quantification.
22. Any image analysis tool can be used for quantifying PLA signals as
the number of fluorescent dots per cell. Typically, use the region of interest (ROI)
tool of the analysis software and define the cytoplasm of the cells with the PLA
signals to quantify. After defining the ROIs, proper thresholding should be
performed to remove background noise and ensure that only PLA signals from
within the defined ROIs are counted by the analysis software. Alternatively,
quantify the number of PLA dots per cell with the Duolink Image Tool software
(Olink Bioscience Co.).
3.2.3 Controls
Control reactions should be performed to ascertain the specificity of PLA
reactions. First, one of the primary antibodies is omitted and the specimen is
incubated with two appropriate PLA probes. In another control reaction, the
specimen is incubated with only the PLA probes and no primary antibodies.
Under both conditions, PLA dots should be absent.
If possible, PLA reactions should also be performed in cells in which one
of the proteins under investigation is not expressed or is downregulated by
siRNA, resulting in an absence of PLA reaction products. Perhaps the best
control is obtained by performing PLA with cells transfected with the cDNA
coding for one of the proteins of interest: evidence for specific PLA reaction is
obtained by the presence of dots in transfected but not in non-transfected cells
(Figure 3.2). Validation of PLA results obtained with one set of primary antibodies
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can also be provided by showing positive PLA reaction with a different set of
primary antibodies. Finally, biochemical methods such as immunoprecipitation
and/or binding assays with purified proteins should be used to confirm PLA
results. It should be kept in mind, however, that some positive PLA results may
reflect interactions between proteins insoluble in immunoprecipitation buffer, in
which case immunoprecipitation does not represent a practical validation method

Figure 3.2: Interaction between synemin and PP2A in U87 cells. PLA demonstrating the
interaction between -synemin and PP2A  subunit in U87 human glioblastoma cells (obtained
from the ATCC), which our lab previously demonstrated (Pitre et al., 2012). U87 cells were
transfected with -synemin tagged with the V5 epitope and PLA was performed with mouse antiV5 and rabbit anti-PP2A A subunit (a). Following the PLA reaction, cells were stained with antimouse IgG conjugated to Alexa Fluor 488 to reveal cells transfected with the synemin construct
(b). DNA was stained with DAPI and appears blue on the micrographs (a and b). PLA dots in the
cell transfected with synemin (arrow) demonstrate interaction between synemin and PP2A A
subunit. The absence of PLA dots in the cells not expressing the synemin construct (arrowhead)
indicates the specificity of the reaction. (c) DIC = Differential Interference Contrast. Bars = 10 m.
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3.3 Conclusions
Current knowledge on synemin indicates that it regulates cellular
behaviors pertaining to growth and survival. Synemin appears to function in
these capacities by interacting with a surprising number of partners, a diversity
enabled by the large size of the tail domain of α- and β-synemin. To further our
understanding of synemin roles, it is important to characterize in-situ the
interaction of synemin with its partners in different cell types and to map the
domains involved. Similar to other IF proteins, most of the cellular synemin is
insoluble in immunoprecipitation buffers. Therefore, this method can only detect
proteins interacting with the small pool of soluble synemin. PLA overcomes this
limitation because it is performed on fixed cells thereby enabling to also analyze
the pool of synemin insoluble in immunoprecipitation buffers. Compared to
FRET, another method for tracking protein-protein interactions in cells, PLA is
simpler to implement and can also be adapted to examine interactions between
different proteins in tissue samples. FRET, however, affords studies of proteinprotein interactions in live cells, whereas PLA can be performed only in fixed
cells.
One of the most important technical considerations for obtaining valid PLA
results is to demonstrate the specificity of the antibodies to be used in PLA
protocols. It is also advised to not omit the optimization steps. When a reliable
PLA positive reaction is obtained, one should keep in mind that this indicates that
the two proteins examined are in close proximity but not necessarily that they
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directly bind to each other. Direct binding can be demonstrated through in vitro
binding assays with purified proteins.

74

Chapter 4: In-situ PLA studies of Synemin Interactions with PP2A and Akt
in Astrocytoma Cells
4.1 Introduction
In addition to providing structural integrity to cells, IF proteins also play
important roles in cell survival, growth, and migration (Robert, Hookway, and
Gelfand. 2016). Several studies have demonstrated that the interplay between IF
proteins and diverse signaling molecules contributes to these non-structural roles
of IF proteins in cells. In this context, nestin (which, like synemin, is a Type VI IF
protein) influences the invasive properties of pancreatic cancer cells by
regulating the spatial localization of phosphorylated focal adhesion kinase
(pFAK) (Hyder et al. 2014). Nestin also contributes to the survival and selfrenewal of neural stem cells (Park et al. 2010) by sequestering cyclin dependent
kinase 5 (CDK5) and inhibiting its proapoptotic function (Sahlgren et al. 2006).
In the liver, keratins 8 and 18 have cytoprotective functions where they
protect hepatocytes from metabolic stress (Toivola et al. 1997; Ku et al. 1998).
Here, the mechanism involves the interaction of these keratins with heat shock
proteins, including Hsp 70, Mrj and Hsp 27 (Coulombe and Wong. 2004). In
mammalian hair follicles, keratin 17 regulates apoptosis by interacting with TNF
receptor 1 (TNFR1)-associated death domain protein (TRADD) (Tong and
Coulombe. 2006). In addition, during wound healing, keratin 17 regulates the
growth of epithelial cells through binding to the adaptor protein 14-3-3σ and
stimulating mTOR activity (Kim, Wong, and Coulombe. 2006).
A role in tissue repair was also demonstrated for vimentin, which interacts
with activated Erk1 and 2 at sites of axonal injury (Perlson et al. 2005). The
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association of Erk 1 and 2 with vimentin facilitates their transport to the cell body
where Erk influences the expression of genes important for repair in injured
neurons (Perlson et al. 2005). In another cellular context represented by prostate
carcinoma cells, vimentin interacts with c-Src, a non-receptor kinase regulating
cell growth and differentiation, and contributes to EMT in these cells (Wei et al.
2008). In vimentin-positive breast cancer cells, vimentin also contributes to EMT.
However, in this context vimentin supports EMT by regulating the expression of
Axl, a tyrosine kinase involved in determining the migratory properties of tumor
cells (Vuoriluoto et al. 2011; Linger et al. 2008).
Studies from our laboratory have shown that synemin also impacts the
cellular behavior of tumor cells by interacting with signaling molecules. This was
suggested by RNAi studies which revealed that synemin downregulation
significantly reduced the proliferation of three different human astrocytoma cell
lines (A172, U373, and U118) without causing apoptosis (Pan et al. 2008; Pitre et
al. 2012). Cell cycle analysis revealed that synemin downregulation leads to an
increase in the number of cells arrested in the G1 phase of the cell cycle and a
reduction in the number of cells in the S phase (Pitre et al. 2012). These cell
cycle changes were caused by alterations in key regulators of the G1/S
transition, namely a decrease in the levels of phosphorylated retinoblastoma (Rb)
protein and an increased accumulation of unphosphorylated cyclin-dependent
kinase inhibitors (CDKI), p21 and p27. Pitre et al. (2012) also showed that the
decrease in phosphorylation levels of p21 and p27 were due to a decrease in the
activity of Akt, which is the upstream kinase responsible for phosphorylating p21
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and p27. That synemin downregulation decreases Akt activity in astrocytomas
was shown by directly measuring the activity of Akt. This was performed by
immunoprecipitating Akt from A172 cells treated with control or synemin shRNAs
and by determining the ability of the immunoprecipitated kinase to incorporate
32

P into one of its substrate, GSK-3 (Pitre et al. 2012). Results of these

experiments showed that synemin downregulation significantly lowered the
activity of Akt in astrocytoma cells (Pitre et al. 2012).
Akt activity is regulated by phosphorylation at S473 by Rictor-mTOR
complex 2 (mTORc2) and at T308 by PIP3-dependent protein kinase 1 (PDPK1)
(Alessi et al. 1996; Sarbassov et al. 2005; Bayascas. 2008). Pitre et al. (2012)
showed that the levels of pS473 and pT308 Akt were markedly decreased in
synemin silenced cells compared to control. However, neither activities nor levels
of mTORc2 and PDPK1 were affected by synemin silencing.
This suggested that the decreased phosphorylation of Akt at S473 and
T308 was due to the increased activity of a protein dephosphorylating Akt. Since
PP2A is the major phosphatase controlling phosphate turnover at S473 and T308
residues of Akt (Arroyo and Hahn. 2005), the activity of PP2A in synemin
silenced astrocytoma cells was compared to that of control cells. The results
showed that the phosphatase activity of PP2A is increased by 180% in
astrocytoma cells treated with synemin shRNA when compared to control (Pitre
et al. 2012). Further proof of a role of PP2A in determining the decreased
proliferation of synemin silenced astrocytoma cells was provided by treating
these cells with cantharidic acid, which is a small molecule inhibitor of PP2A
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(Honkanen. 1993). The results of these experiments did demonstrate that
cantharidic acid restored the proliferation and Akt activity in synemin silenced
astrocytoma cells to levels similar to those of control cells (Pitre et al. 2012).
To begin understanding the molecular mechanism by which synemin
influences PP2A activity, Pitre et al (2012) conducted a series of
immunoprecipitation experiments. PP2A is a multisubunit protein that comprises
a structural subunit A, a regulatory subunit B, and a catalytic subunit C (Shi.
2009; Virshup and Shenolikar. 2009). While many different types of B subunits
exist, B55 determines PP2A specificity for Akt (Kuo et al. 2008).
Immunoprecipitation of naïve A172 astrocytoma cell lysates with synemin
antibodies pulled down subunits A and B55 of PP2A along with  and -synemin
(Pitre et al. 2012). To determine whether synemin formed a complex with the
individual PP2A subunits or with the holoenzyme, immunoprecipitation
experiments were carried out with antibodies against PP2A A or B55 subunits.
These experiments showed that, indeed, synemin does precipitate with PP2A A
as well as B55 subunits. Altogether, these results led us to hypothesize that
synemin could regulate astrocytoma proliferation by forming a complex with
PP2A and regulating its interaction with Akt.
The goal of this part of the dissertation was to examine this hypothesis insitu by using PLA (see Chapter 3). With this technique we aimed to determine
the cellular compartments in which the interaction between synemin and PP2A,
on the one hand, and between PP2A and Akt, on the other hand, take place. The
results of these PLA studies are presented in this chapter and were published in

78

Molecular Biology of the Cell (2012 vol. 23, 1243-1253) in the article entitled
“Synemin promotes Akt-dependent glioblastoma cell proliferation by antagonizing
PP2A” (Pitre et al. 2012).
In this chapter, we also describe studies aimed at mapping the amino-acid
domain of synemin involved in mediating the interaction between synemin and
PP2A. Synemin is an IF protein with a large C-terminus that has been shown to
bind several cellular proteins (see Chapter 1, subsection 1.4.3). However, we
know very little about the domains involved in the interaction between synemin
and its binding partners. Thus, we aim to identify C-terminal subdomain(s) of
synemin that is/are critical in determining the binding of synemin to PP2A. For
these studies we examined whether synemin deletion constructs bind to PP2A.
Binding of PP2A to the protein encoded by these constructs was assessed by
PLA and proliferation assays. Constructs having lost the ability to bind PP2A
would not give PLA reaction products and would not rescue the proliferation of
synemin silenced cells.
4.2 Material and Methods
4.2.1 Cell Culture
Synemin-positive human A172 and synemin-negative human U87
astrocytoma cells (ATCC, Rockville, MD) were grown in Dulbecco’s minimum
essential medium (DMEM) (Invitrogen, Carlsbad, CA) containing 10% fetal calf
serum (FCS) (Invitrogen, Carlsbad, CA) and 100 U/ml penicillin and 100 ug/ml
streptomycin (PS) (Lonza, Walkersville, MD).
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4.2.2 RNAi with Synemin shRNA
RNAi of synemin in A172 cells was performed by lentiviral delivery of
shRNAs cloned into the vector pLKO.1-puro as described (Pan et al. 2008). The
shRNAs targeted the human synemin sequences 5’CGCTTACAGTACCATTTCATT-3’ (synemin shRNA 1) and 5’GCCGTCAGAATTCAGAAACAA-3’ (synemin shRNA 2). Control shRNA was
represented by the sequence
5’-CAACAAGATGAAGAGCACCAA-3’, which is not present in the human
genome.
The synemin shRNA was packaged into lentivirus particles using the
ViraPower Lentivirus Expression System (Invitrogen, Carlsbad, CA) following
manufacturer’s instructions. The titer of the lentivirus was determined with the
Lenti-X GoStix kit (Clontech, Mountain View, CA) and found to be at least 5x10 5
infection forming units/ml (IFU/ml).
To transduce cells with lentiviral particles encoding synemin shRNA, A172
astrocytoma cells were plated at a density of 50,000 cells per well of a 6-well
plate. On the day of the experiment, the culture medium was removed and
lentivirus, diluted in fresh medium with polybrene (6 g/ml final) (Sigma, St.
Louis, MO), was added to each well of the culture plate. Cells were infected with
the lentivirus at a multiplicity of infection (MOI) of 2. Polybrene is a cationic
polymer that increases the efficiency of infecting the cells with lentivirus (Denning
et al. 2013; Davis, Morgan, and Yarmush. 2002). The cells were incubated with
the virus for 24 hours, after which the culture medium containing the virus was
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replaced with fresh medium. The following day, A172 cells transduced with the
synemin shRNA lentivirus were treated with 1 µg/ml puromycin (Sigma, St. Louis,
MO) for 8 days to select for stable incorporation events. After selection, the cells
were used for the assays described below.
4.2.3 Generation of Synemin Deletion cDNAs and Cloning into pLenti6/V5D-TOPO.
To package full length -synemin cDNA (SB1-1253) into lentivirus, we
subcloned β-synemin cDNA that was previously cloned into the pTrcHis plasmid
(Jing et al. 2007), into the mammalian lentiviral expression vector pLenti6/V5-DTOPO (Invitrogen, Carlsbad, CA) by topocloning using the primer pair listed in
Table 4.1. SB1-1253 construct was designed to include a V5 tag at the Cterminus.
Using the primer pairs detailed in Table 4.1 below, we had amplified and
cloned the cDNAs of β-synemin mutants that contained varying lengths of amino
acid sequences, into the pLenti6/V5-D-TOPO plasmid vector (Figure 4.1). These
constructs also included a V5 tag at their C-terminus. DNA sequencing was
performed by Retrogen Inc. (San Diego, CA) to verify the sequence of the cDNA
clones.
Following cloning, the pLenti6/V5-D-TOPO expression vector was
packaged into lentiviral particles, as described in section 4.2. 2, to transduce and
express the SB1-1253, SB1-1028 and SB1-384 constructs in synemin silenced
A172 and synemin-null U87 astrocytoma cells. The U87 cells were maintained in
g/ml of blasticidin (Invitrogen, Carlsbad, CA) and synemin silenced A172 cells
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were maintained in g/ml of puromycin and g/ml of blasticidin for 7 days to
select for cells that were stably expressing the transgene.
4.2.4 Site-directed Mutagenesis to Generate a Synemin cDNA with an
Internal Deletion.
The nucleotide sequence encoding amino acids 350-700 was deleted from
full length -synemin (SB1-1253) cloned into pLenti6/V5-D-TOPO (see section
4.2.3 above) using the Quick Change XL Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA) and the primers listed in Table 4.1. DNA
sequencing was performed by Retrogen Inc. (San Diego, CA) to verify that amino
acids 350-700 were deleted from SB1-1253 sequence.
The internal deletion construct, SB350/700-int-del, was then packaged
into lentivirus following the protocol described in section 4.2.2. Synemin silenced
A172 cells and wildtype U87 cells were transduced with lentiviruses containing
the SB350/700-int-del construct. Synemin silenced A172 cells transduced with
lentivirus containing SB350/700-int-del, were maintained in 1 µg/ml puromycin
and 5g/ml of blasticidin (Invitrogen, Carlsbad, CA) to select for cells stably
expressing the SB350/700-int-del construct. U87 cells that were transduced with
lentivirus containing the internal deletion construct were maintained in 5g/ml of
blasticidin for stable transgene expression.
4.2.5 Immunofluorescence Staining and PLA
For immunofluorescence staining and PLA on control and syneminsilenced A172 cells and on U87 cells expressing the various synemin constructs,
cells were plated on glass coverslips at similar densities. For both
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immunofluorescence and PLA, cells were fixed in 4% paraformaldehyde and
permeabilized in 0.1% NP-40 as detailed by (Jing et al. 2005).
Immunofluorescence with synemin and PP2A antibodies was performed
following standard protocol (Jing et al. 2005). In-situ PLA (Fredriksson et al.
2002) was carried out with the Duolink Detection kit (Olink Bioscience, Uppsala,
Sweden) according to the manufacturer's instructions and as described in detail
in Chapter 3, subsection 3.2.2. Briefly, fixed and permeabilized cells were
incubated for 30 minutes at 37°C in blocking solution. Next, they were incubated
with the appropriate combination of affinity purified goat anti-synemin (1:10),
affinity-purified rabbit anti-synemin (1:5000 to 1:10,000) (Jing et al. 2005), mouse
anti-Akt (1:10) (Cell Signaling Technology, Danvers, MA), and rabbit anti-PP2A A
subunit (1:10) (Cell Signaling Technology, Danvers, MA), mouse anti-PP2A A
subunit (1:50) (Santa Cruz Biotechnologies, Santa Cruz, CA) for 60 minutes at
25°C. After washes, cells were incubated for 60 minutes at 37°C with appropriate
PLA probes, consisting of secondary antibodies (anti-mouse, anti-rabbit and antigoat) conjugated to oligonucleotides (Fredriksson et al. 2002). Following washes,
circularization and ligation of appropriate oligonucleotides were performed in
ligase-containing solution for 30 minutes at 37°C. Cells were then rinsed briefly
and incubated for 90 minutes at 37°C with the amplification solution prior to
hybridizing the amplified product with complementary probe labeled with Alexa
568.
For immunofluorescence and PLA with control and synemin silenced
astrocytoma, cells were counterstained with phalloidin-Alexa 488 or 633 (1:500)

83

(Invitrogen, Carlsbad, CA) and donkey anti rabbit secondary antibody conjugated
with Alexa 488 (Jackson Immunoresearch, West Grove, PA), respectively. U87
cells that were stained for immunofluorescence were incubated with mouse antiV5 antibody, diluted 1:250 in PBS, for 30 minutes at room temperature. This was
followed by three washes in phosphate buffered saline (PBS) (Sigma, St. Louis,
MO) solution for 5 minutes each. Next, the cells were incubated with donkey antimouse secondary antibody conjugated with Alexa-488 (Jackson
Immunoresearch, West Grove, PA) After PBS washes, coverslips were mounted
with Prolong Antifade containing DAPI (Molecular Probes; Carlsbad, CA).
Observations were carried out with a Nikon A1 laser-scanning confocal
microscope. Representative results are shown from experiments repeated at
least three times.
4.2.6 Western Blotting
Determination of expression of full SB1-1253, SB1-1028, SB1-384 and
SB350/700-int-del constructs in U87 astrocytoma cells was performed by
western blotting using cell lysates prepared in Laemmli sample buffer (Laemmli,
1970). The protein concentration of the lysates was determined with the
bicinchoninic acid (BCA) reagent (Pierce, Rockford, IL) (Smith et al. 1985). Gel
electrophoresis was then performed with 1 μg of total cellular proteins loaded
onto the lanes of 4-15% SDS-polyacrylamide gradient gels (Biorad, Hercules,
CA). The electrophoretic separation of proteins was performed at a constant
voltage of 200 V for 30 minutes. After electrophoresis, the proteins separated in
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the gel were transferred onto nitrocellulose membranes at a constant voltage of
100 V for 1 hour.
After the transfer, the nitrocellulose blots were incubated for 1 hour in 5%
milk in PBS (PBS-milk) to block non-specific binding sites. Next, the blots were
incubated for 1 hour at room temperature with primary antibodies diluted in PBSmilk as follows: 1:500 for mouse anti-V5 epitope (Abcam, Cambridge, MA).The
blots were then washed with PBS three times for 5 minutes each. Next, the blots
were incubated for 1 hour at room temperature in the goat anti-mouse secondary
antibody conjugated to horseradish peroxidase (Jackson Immunoresearch, West
Grove, PA) and diluted 1:500 in PBS-milk. At the end of the incubation, the blots
were washed with PBS three times for 5 minutes each. The peroxidase activity
was detected with by a colorimetric reaction using tetramethylbenzidine as a
substrate (Kirkegaard & Perry, Gaithersburg, MD).
4.2.7 Proliferation Assay
A172 cells silenced with synemin shRNA were selected according to the
protocol described in section 4.2.2. These cells were then transduced with SB11253, SB1-1028, SB1-384 and SB350/700-int-del constructs and selected with 1
µg/ml puromycin and 5g/ml of blasticidin (Invitrogen, Carlsbad, CA) for 8 days.
For proliferation assays, cells were plated at a density of 5000 cells/well of
a 24-well plate (Thermo Fisher, Waltham, MA). The cells were allowed to adhere
to the bottom of the wells overnight, after which they were trypsinized,
resuspended in complete medium, and counted with a hemocytometer. This was
considered to be the cell count on day 0. After this, cells were trypsinized 2, 4,
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and 6 days after the day 0 counts, resuspended in complete medium, and
counted with a hemocytometer.
Table 4.1: List of primers. -synemin and the various deletion constructs were cloned using the
forward and reverse primer pairs listed in this table.

Construct

Forward primer

Reverse primer

SB1-1253

5’-CACCGGGACAA

5’-AAACCAATGCCCAT

GACCAGGGCAGGA-3’

CATTCTCCTC-3’

5’-CACCGGTATGC

5’- CTCCATCTCACTG

TGTCCTTGCGGCTG-3’

GCCTCATC-3’

5’- CACCGGGACAA

5’- CGTCTGAGATCCAC

GACCAGGGCAGGA-3’

GGTGCCCA-3’

SB350/700

5’-CCGACTCACTACTAGA

5’- CCAGGCCAGCTTCTAGT

-int-del

AGCTGGCCTGG-3’

AGTGAGTCGG-3’

SB1-1028

SB1-384

Figure 4.1: Full length -synemin and various deletion mutants that were cloned into
pLenti6/V5-D-TOPO plasmid vector and tested for their interaction with PP2A. SB1-1253 is
full length -synemin. SB1-1028 consists of amino acids 1-1028, and SB1-384 consists of amino
acids 1-384 of -synemin, respectively. In the construct SB350/700-int-del, amino acids 350-700
were deleted from full length -synemin.
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4.3 Results
4.3.1 Synemin Associates with PP2A to Regulate PP2A Subcellular
Distribution and Interaction with Akt.
Synemin and PP2A interactions were evidenced in-situ in A172
astrocytoma cells by immunofluorescence staining and PLA. First,
immunofluorescence staining showed that synemin down-regulation altered cell
shape from polygonal (Figure 4.2 A) to elongated with long cellular processes
(Figure 4.2 E). In both cases synemin localizes with the vimentin IF network, the
nuclear area, and is also present at the cell periphery in leading edges and
ruffled membranes (Figure 4.2 B).
In control A172 cells, PP2A antibodies stained the nuclear region (Figure
4.2 C) and in that area the staining of PP2A and synemin overlapped (Figure 4.2
D). In synemin-silenced cells, PP2A antibodies stained the cytoplasm as well
(Figure 4.2 G). Proximal ligation assays (PLA) with synemin and PP2A
antibodies indicated that, consistent with immunofluorescence results (Figure
4.2C), the nuclear area was indeed the major site of synemin and PP2A
interactions because most PLA reaction products concentrated in that region
(Figure 4.2 A). In contrast, in synemin silenced cells, there were few synemin and
PP2A PLA reaction products (Figure 4.3 B), which shows the specificity of the
PLA reaction.
Interestingly, PLA revealed that synemin silencing modified PP2A and Akt
interactions. In control cells, PLA reaction products obtained with PP2A and Akt
antibodies were scarce and localized primarily in the nuclear area (Figure 4.3 C).
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In contrast, in synemin-silenced cells, PP2A and Akt antibodies PLA reaction
products abounded and distributed throughout the cytoplasm (Figure 4.3 D).
Control experiments were carried out by omitting one of the two primary
antibodies from the PLA protocol; under these conditions, PLA fluorescent
amplification products were absent (data not shown).

Figure 4.2: Cellular distribution of synemin and PP2A shown by fluorescent staining of
A172 cells treated with control (A-D) or synemin (E-H) shRNAs. Staining was performed with
four fluorescent reagents including: phalloidin Alexa 633 (to stain actin; in purple) and DAPI (to
stain DNA; in blue) (A, E), Alexa 488 synemin antibodies (in green) (B, F), and Alexa 568 PP2A
antibodies (in red) (C, G). (A, E): Actin staining shows that control cells are polygonal in shape
with prominent peripheral actin (A, arrowheads), whereas synemin-silenced cells have an
elongated cell body with cytoplasmic processes (E). (B, F): Staining with synemin antibodies
shows that in control cells synemin is localized at the cellular periphery (B, arrowheads) as well
as in the nuclear area (B, arrows); synemin staining is decreased after synemin silencing (F). (C,
G): Staining with PP2A antibodies shows that PP2A is present in the nuclear area of control cells
(C, arrows); after synemin silencing, PP2A antibodies stain the cytoplasm as well (G, v-shaped
arrowheads). (D, H): overlay of synemin and PP2A staining appears yellow and reveals that the
two proteins overlap in the nuclear area of control cells (D, arrows); little overlap is seen in
synemin-silenced cells (H). Bars = 10 m.
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Figure 4.3: Synemin affects cellular location of PP2A and its interaction with Akt. Proximal
ligation assays (PLA) performed with antibodies against PP2A and synemin (A,B) or with
antibodies against PP2A and Akt (C,D) in A172 cells treated with control (A,C) or synemin (B,D)
shRNAs. PLA reaction products appear as red dots in cells where boundaries and nuclei were
stained with phalloidin-Alexa 488 (green) and DAPI (blue), respectively. (A, B): PLA reaction
products for PP2A and synemin localize primarily in the nuclear area of control cells (A) while
fewer reaction products appear in the nuclear area of synemin-silenced cells (B). (C, D): PLA
reaction products for PP2A and Akt are scarce in control cells (C), but numerous in synemin
silenced cells (D) where they localize in the cytoplasm (D, arrowheads). Bars = 10 m.

89

4.3.2 Synemin Binding to PP2A Involves amino acids 700-1028 in the Cterminus of Synemin
Synemin is a large, 1253 amino-acids, IF protein. To understand the
molecular basis of synemin interaction with PP2A, we initiated experiments to
identify the region of synemin involved in binding to PP2A. To this end, we
subcloned full length -synemin and -synemin mutants lacking distal portions of
the C-terminus, or with internal deletion, into pLenti6/V5-D-TOPO vector such
that they would contain a V5 epitope tag at their C-terminus. At first, we stably
expressed constructs SB1-1253 (full length -synemin), SB1-1028 (containing
amino acids 1-1028), SB1-384 (containing amino acids 1-384), and SB350/700int-del (-synemin missing amino acids 350-700) in U87 astrocytoma cells, which
do not express endogenous synemin. Immunofluorescence (Figure 4.4 A-D) and
Western blotting (Figure 4.4 E) with V5 antibodies demonstrated that U87 cells
expressed these constructs.

90

Figure 4.4: Expression of full length -synemin and the various deletion constructs in U87
astrocytoma. (A-D) Immunofluorescent staining showing stable expression of SB1-1253, SB11028, SB1-384 and SB350/700-int-del constructs in U87 cells. (E) Transgene expression was
confirmed by Western blotting on whole cell lysate of U87 cells expressing each construct. Bar=
10M.
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PLA was then performed to determine which of these constructs
interacted with PP2A. These experiments showed that full length -synemin
(SB1-1253) had a robust interaction with PP2A as signified by the large number
of red PLA reaction products in cells expressing the construct (labeled in green)
(Figure 4.5 A). The deletion construct SB1-1028 interacted with PP2A to a level
similar to that of to SB1-1253 as demonstrated by quantification of PLA dots
(Figure 4.5 B and E). However, SB1-384 had significantly (p= 0.0029) reduced
interaction with PP2A compared to SB1-1253 as shown by a 70% reduction in
the number of PLA dots in cells transduced with SB1-384 (Figure 4.5 C and E).
Altogether, these results indicate that the PP2A binding site on synemin is
comprised between amino acids 384 and 1028.
To further narrow down which part synemin amino acids 384 and 1028
binds to PP2A, we generated by site-directed mutagenesis, a -synemin internal
deletion mutant, SB350/700-int-del, in which amino acids 350-700 were missing.
Interestingly, SB350/700-int-del showed robust interaction with PP2A as
demonstrated by the fact that the number of PLA dots per cells transfected with
this mutant was similar to the number of dots in cells transfected with the full
length construct (Figure 4.5 D). Taken with the PLA results obtained with SB11028 and SB 1-384, these results indicate that the PP2A binding region on
synemin lies between amino acids 700 and 1028 (Table 4.2).
To validate this conclusion with an alternate assay, we performed
proliferation rescue experiments using A172 astrocytoma cells silenced for
synemin with shRNAs and in which the different synemin cDNA constructs were
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introduced. As previously shown (Pan et al. 2008; Pitre et al. 2012), silencing
synemin strongly reduced the proliferation of A172 cells. However, proliferation
was increased to levels similar to those of A172 cells when synemin silenced
A172 cells were transduced with lentivirus expressing full-length -synemin
(construct SB1-1253) or synemin deletion constructs SB1-1028 and SB350/700int-del (Figure 4.6 A). In contrast, transduction with construct SB1-384 did not
rescue the proliferation of synemin silenced A172 astrocytoma cells (Figure 4.5
B). In fact, the rate of proliferation of synemin silenced A172 cells expressing
SB1-384 was similar to that of synemin silenced cells (Figure 4.6 B).
Altogether, the results of these proliferation rescue experiments support
the results of the PLA experiments indicating that the PP2A binding region on
synemin lies between amino acids 700 and 1028 (Table 4.2).
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A

SB 1-1253

B

SB 1-1028

C

SB 1-384

D

SB 350/700-int-del

E

Figure 4.5: The PP2A binding site on synemin is located between amino acids 700 and
1028 in the C-terminus. PLA reaction products appear as red dots in cells which express the
respective synemin construct (green). Cell nuclei were stained with DAPI (blue). (A, B and D):
PLA reaction products are similar in SB1-1253, SB1-1028 and SB350/700-int-del suggesting that
these constructs bind to PP2A. (C): PLA reaction products are few in U87 cells that are
expressing SB1-384 when compared to SB1-1253 expressing cells. (E): Histogram showing that
the average number of PLA reaction products in U87 cells expressing SB1-384 was significantly
less compared to cells expressing SB1-1253 (p= 0.002), SB1-1028 (p= 0.01), and SB350/700-intdel (p= 0.002). Data represents mean ± SEM from 3 independent experiments. Scale bars = 10
m.
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Figure 4.6: Proliferation of synemin silenced astrocytoma is not rescued by SB1-384.
Proliferation curves show that SB1-1253, SB1-1028 and SB350/700-int-del rescue the
proliferation of synemin silenced A172 cells (A), but that the proliferation of these cells is not
rescued by SB1-384 (B). Results represent mean ± SEM of 3 independent experiments.
Table 4.2: Summary of proliferation and PLA results. Constructs SB1-1253, SB1-1028 and
SB350/700-int-del interact with PP2A and rescue proliferation of synemin silenced astrocytoma
cells. SB1-384 has reduced binding to PP2A and does not rescue proliferation of synemin
deficient astrocytoma.
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4.4 Discussion
The contribution of synemin in the malignant phenotype of astrocytomas
was first suggested by the finding that synemin is not expressed in normal,
mature astrocytes but is found in astrocytoma tumors (Jing et al. 2005; Skalli et
al. 2013). Later, RNAi experiments demonstrated that synemin positively
influences the motility and proliferation of astrocytoma cells (Pan et al. 2008).
Pitre et al. (2012) then showed that synemin contributes to astrocytoma
proliferation by antagonizing PP2A activity, which ensures that Akt remains in an
active, phosphorylated state and allows astrocytoma cells to complete the cell
cycle and proliferate. This was demonstrated by the decreased phosphatase
activity of the PP2A holoenzyme immunoprecipitated from synemin silenced
A172 astrocytoma cells as compared to naïve A172 cells.
Results from our current investigations provide mechanistic insight on the
interaction between synemin and PP2A by demonstrating by PLA that these two
proteins physically interact with each other in astrocytoma cells. PLA further
demonstrates that the interaction between synemin and PP2A takes place in the
nuclear region. This result is consistent with immunofluorescence results
showing that in control cells, PP2A and synemin co-localize in the nuclear region.
We cannot exclude at this point the presence of a pool of synemin in the nucleus
and therefore, additional investigations are needed to determine whether
synemin and PP2A interact in the nucleus and/or in the perinuclear region.
Immunofluorescence also showed that synemin silencing altered the
cellular localization of PP2A. In control cells expressing synemin, PP2A staining
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was predominantly in the nuclear region. Upon synemin silencing, PP2A was
seen distributed in the cytoplasm of the cell. The fact that some of the PP2A
staining remained in the nuclear area after synemin silencing suggests that,
synemin may interact with a subset of PP2A, perhaps one containing a particular
B subunit isoform that has a predominantly cytoplasmic distribution. The B
regulatory subunit of PP2A determines the subcellular localization of the PP2A
holoenzyme. For instance, the majority of the PP2A-B55 regulatory subfamily is
present in the cell cytoplasm and approximately 5% is present in the nucleus
(Turowski et al. 1999). However, the PP2A-B56y1-3 isoforms are nuclear in their
distribution (McCright et al. 1996; Kiely and Kiely. 2015). In any case, PLA
demonstrated that synemin silencing increased PP2A and Akt cytoplasmic
interactions. This increase in PP2A and Akt interaction accounts for the
decreased Akt phosphorylation following synemin downregulation, as was
demonstrated by Pitre et al (2012).
Altogether, these results indicate that synemin regulates PP2A activity by
specifying its subcellular distribution in a manner that sequesters it from Akt,
which allows Akt to remain phosphorylated and in an active state. This is in
keeping with recent reports showing that dynamic redistribution of PP2A with
different B-subunit compositions, between the cytoplasm and nucleus during the
cell cycle regulates progression of cells from G1 to S phase and also mitotic exit
(Lee et al. 2010; Rossio and Yoshida. 2011).
We have also demonstrated with PLA and with proliferation rescue
assays, that the specific interaction between PP2A and synemin is mediated by a
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region that lies between amino acids 700-1028 in the C-terminus of the synemin
protein. Synemin has a long C-terminal region which has been shown to interact
with different cellular proteins, such as plectin I (Hijikata et al. 2008), -actinin
(Bellin et al. 1999; Bellin et al. 2001), zyxin (Sun et al. 2010) which are actin
binding proteins, and the regulatory protein PKA (RII) (Russell et al. 2006).
These proteins bind to synemin at different locations on the C-terminus (Figure
4.7). For instance, plectin I binding site is between amino acids 303-432, zyxin
and -actinin both bind to a region between amino acids 920-1253, and PKA
binds between amino acids 556-707. Therefore, the PP2A binding site on
synemin between amino acids 700-1028, is unique and not shared by any known
synemin binding partner.
The actin-binding proteins that bind to synemin are phospho-proteins and
one of the kinases involved in their phosphorylation is PKA (Howe. 2004;
Bouameur et al. 2013). Similarly, synemin is itself a substrate for phosphorylation
by PKA (Sandoval, Colaco, and Lazarides. 1983). Co-incidentally, it has also
been shown that PP2A plays an important role in dephosphorylating plectin-I and
regulating how plectin-I anchors IF proteins along cell-substrate contacts
(Bouameur et al. 2013). Thus, we think that by binding to PKA (RII) and PP2A,
synemin not only regulates the phosphate turnover on itself, but also positions
PKA (RII) close to its cytoskeletal targets to regulate actin dynamics. Therefore,
it is possible that in astrocytoma cells, synemin acts as a scaffold and binds
kinases and phosphatases, in addition to actin binding proteins. In this manner,
synemin can influence actin dynamics by phosphorylation/dephosphorylation of
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the actin binding proteins to regulate migration in astrocytoma cells and also
participates in controlling Akt signaling to regulate proliferation of these cells.

Figure 4.7: Binding sites of various actin binding proteins, PKA, and PP2A on C-terminus
of synemin. The long C-terminus of synemin has binding sites for actin binding proteins plectin I
(amino acids 303-432), zyxin and -actinin (both between amino acids 920-1253). PKA (RII)
binds between amino acids 556-707. PP2A binds between amino acids 700-1028.
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Chapter 5: Overall Conclusion
We demonstrate that the synemin isoforms , - and L are expressed in
three cancer cell lines of different cellular origin and that the / ratio varies
between these cell lines. We also demonstrate that - and -synemin are
regulated in a cell-type dependent manner by agents that control the
differentiation status of tumor cells (L-synemin was not investigated in these
studies due to unavailability of antibodies). Retinoid and Notch signaling
pathways that induce differentiation of HeLa carcinoma and N2a neuroblastoma
cells, decrease synemin in these cells. However, TGF-, which induces dedifferentiation of astrocytoma tumors, increases synemin level in these cells.
TGF- is also known to increase motility and proliferation of astrocytic tumors.
Therefore, we suggest that one of the ways by which TGF- increases the
motility and proliferation of astrocytoma cells is by increasing synemin levels in
these cells. Synemin, in turn, affects astrocytoma proliferation by interacting with
PP2A to localize PP2A to the nuclear region and reduce its interaction with Akt,
thereby enabling robust cell proliferation. Furthermore, our results show that the
interaction between PP2A and synemin involves a 328 amino acid domain in the
C-terminus of synemin.
Based on our results, we propose that synemin functions as a scaffolding
protein in astrocytoma cells. A potential mechanism for that activity is that
synemin, via different domains along its long C-terminus, binds to cytoskeletal
proteins important in regulating actin dynamics as well as with signaling
molecules such as PKA and PP2A. Therefore, the results presented in this
100

dissertation, combined with all available evidence on synemin, suggest that by
binding to PKA and PP2A, synemin spatially regulates the activity of these
proteins to control cytoskeleton-dependent processes, such as motility, and
governs astrocytoma proliferation by regulating Akt phosphorylation and activity.
Synemin may have a similar role, that of a scaffolding protein, in N2a and
HeLa cells where synemin interacts with signaling molecules that are involved in
cellular differentiation. For instance, in undifferentiated neuroblastoma cells, a
stable complex between the retinoic acid receptor (RAR), p85 regulatory subunit
of PI3K, and other unknown proteins is formed (Masia et al. 2007). When ATRA
is added to these neuroblastoma cells, p110 catalytic subunit of PI3K also binds
to the stable complex to promote activation of PI3K leading to downstream
activation of Akt (Masia et al. 2007). This in turn induces neuroblastoma
differentiation (Qiao et al. 2012). We speculate that in undifferentiated
neuroblastoma, synemin may interact with p110 and prevent its association to
the stable complex between p85 and RAR. However, when ATRA binds to RAR,
synemin levels decrease in the tumor cells to release p110 and allow it to bind to
the stable complex and activate PI3K. Similar to the effects of ATRA, inhibiting
Notch signaling also causes differentiation of N2a neuroblastoma cells (Zage et
al. 2012). However, the role of Notch in neuroblastoma tumor cell differentiation
is not very well understood. Considering that both ATRA and Notch mediate their
cellular effects by activating transcription factors that up/down regulate target
gene activity, it is possible that some of these transcription factors may also
regulate synemin gene expression in neuroblastoma and HeLa cells. Therefore,
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future studies should determine the mRNA level of synemin isoforms following
ATRA treatment and Notch inhibition in these cells, and analyze transcription
factors that regulate synemin gene expression.
Synemin is expressed in several different types of cells, including
muscles, endothelial cells, stellate liver cells, astrocyte progenitor cells, and
some adult neuronal cells. Recently, Moorer et al., 2016, reported synemin
expression in osteoblast. It is interesting to note that the role of synemin is varied
in these cells. In skeletal muscles, synemin functions as a structural protein and
connects muscle specific IFs to various specialized structures important in
organizing myofibrills, such as Z-lines and costameres. However, in
cardiomyocytes synemin functions as an AKAP to regulate PKA activation.
Previous results from our laboratory and the work presented in this dissertation
have shown that in astrocytoma cells synemin may function as a scaffolding
protein that binds to PP2A to regulate astrocytoma cell proliferation. In N2a
neuroblastoma and HeLa cervical carcinoma our results indicate that synemin is
involved in the differentiation of these cells. That synemin plays a similar role in
differentiation and proliferation of osteoblast cells was indicated by studies in
synemin-null mice (Moorer et al. 2016). However, the molecular mechanism by
which synemin affects bone formation remains unknown. Therefore, the
information presented in this dissertation showcases the multiplicity of roles that
synemin has in cells expressing this protein. Future studies to systematically
investigate the mechanism behind the newly defined cellular functions of
synemin merits further study.

102

Our work also demonstrates the utility of the PLA technique to study
protein-protein interaction in-situ, and in particular interactions of proteins which,
like synemin and IF proteins in general, are mostly insoluble in
immunoprecipitation buffer. However, given the high sensitivity of the PLA
technique, we also demonstrate that it is important to perform preliminary titration
and optimization experiments. We emphasize the use of a number of controls in
order to determine conditions in which it will not yield false positive. We also used
PLA to determine the region on synemin involved in binding to PP2A and for
these experiments verified the PLA results with proliferation rescue assays.
Thus, our work establishes PLA as an invaluable tool to study the interactions
between IF proteins and other proteins.
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